Table of Contents

PART I. BACKGROUND AND GENERAL ANTITRUST PRINCIPLES

CHAPTER 1. GENERAL BACKGROUND

§ 1:1 Synopsis and introduction
§ 1:2 Purpose and definition of the antitrust laws
§ 1:3 Overview and history of the antitrust laws
§ 1:4 The goals of antitrust
§ 1:5 Is health care different?
§ 1:6 History of antitrust enforcement in the health-care sector
§ 1:7 Current health-care antitrust enforcement initiatives
§ 1:8 Federal government antitrust guidelines
§ 1:9 Conclusion
§ 1:10 Antitrust resources

CHAPTER 2. INTERSTATE COMMERCE AND RELEVANT ANTITRUST MARKETS

§ 2:1 Synopsis and introduction
§ 2:2 The interstate commerce requirement
§ 2:3 Relevant antitrust markets
§ 2:4 —Relevant product market
§ 2:5 —Relevant geographic market
§ 2:6 Conclusion

CHAPTER 3. SECTION 1 OF THE SHERMAN ANTITRUST ACT: FUNDAMENTAL CONCEPTS

§ 3:1 Synopsis and introduction
§ 3:2 Elements of a section 1 violation
§ 3:3 —Agreement
§ 3:4 — —Nature of the agreement

§ 3:5 — —Capacity to conspire
§ 3:6 — —Conspiracy in fact
§ 3:7 —Anticompetitive purpose or intent
§ 3:8 — —Purpose and intent in civil antitrust cases
§ 3:9 — —Intent in criminal antitrust cases
§ 3:10 —Unreasonably anticompetitive effect
§ 3:11 — —The rule of reason
§ 3:12 — —The per se rule
§ 3:13 — —Hybrid analyses—The "quick look" rule
§ 3:14 The antitrust guidelines for collaborations among competitors

CHAPTER 4. SECTION 1 OF THE SHERMAN ANTITRUST ACT: HORIZONTAL AGREEMENTS

§ 4:1 Synopsis and introduction
§ 4:2 Horizontal price-fixing agreements
§ 4:3 Agreements to exchange or disseminate information
§ 4:4 Horizontal market-allocation agreements
§ 4:5 Bid-rigging agreements
§ 4:6 Covenants not to compete
§ 4:7 Concerted refusals to deal
§ 4:8 Mergers and joint ventures
§ 4:9 Unfair competition and "dirty tricks"
§ 4:10 Standard-setting programs

CHAPTER 5. SECTION 1 OF THE SHERMAN ANTITRUST ACT: VERTICAL AGREEMENTS

§ 5:1 Synopsis and introduction
§ 5:2 Vertical price-fixing agreements
§ 5:3 Vertical market-allocation agreements
§ 5:4 Distributorship terminations
§ 5:5 Dual distribution
§ 5:6 Tying agreements
§ 5:7 Exclusive dealing agreements
§ 5:8 Reciprocal dealing agreements
§ 5:9 Price discrimination and commercial bribery

CHAPTER 6. SECTION 2 OF THE SHERMAN ACT

§ 6:1 Synopsis and introduction
§ 6:2 Monopolization
§ 6:3 —Monopoly power
§ 6:4 —Anticompetitive conduct
§ 6:5 — —Monopoly pricing
§ 6:6 — —Predatory pricing
§ 6:7 — —Refusals to deal
§ 6:8 — —Denial of access to an essential facility
§ 6:9 — —Leveraging
§ 6:10 — —Vertical integration
§ 6:11 — —Mergers
§ 6:12 — —Other predatory or unreasonably exclusionary conduct
§ 6:13 Attempted monopolization
§ 6:14 —Specific intent and predatory conduct
§ 6:15 —Dangerous probability of success
§ 6:16 Conspiracy to monopolize
§ 6:17 "Shared monopoly"

CHAPTER 7. PRICE DISCRIMINATION, INTERLOCKING DIRECTORATES, AND UNFAIR METHODS OF COMPETITION

§ 7:1 Synopsis and introduction
§ 7:2 The Robinson-Patman Act—Overview
§ 7:3 —Section 2(a)—Essential elements
§ 7:4 — —Jurisdictional requirements
§ 7:5 — —Competitive effects
§ 7:6 — —Defenses
§ 7:7 —Section 2(c)
§ 7:8 —Sections 2(d) and 2(e)
§ 7:9 —Section 2(f)
§ 7:10 —Exemptions and applicability
§ 7:11 —Injury in private treble-damage litigation
§ 7:12 Section 8 of the Clayton Act
§ 7:13 The Federal Trade Commission Act

CHAPTER 8. SECTION 7 OF THE CLAYTON ACT: MERGERS AND ACQUISITIONS

§ 8:1 Synopsis and introduction

§ 8:2 Preliminary issues
§ 8:3 An overview of merger analysis and the effect of the 2010 *Merger Guidelines*
§ 8:4 Relevant markets
§ 8:5 Horizontal mergers
§ 8:6 —Concentration
§ 8:7 —Other factors
§ 8:8 — —Rebuttal evidence
§ 8:9 — — —Entry
§ 8:10 — — —Market characteristics and ease of collusion
§ 8:11 — — —Financial viability
§ 8:12 — — —Efficiencies from the merger
§ 8:13 —Defenses
§ 8:14 Vertical mergers
§ 8:15 Conglomerate mergers
§ 8:16 Joint ventures
§ 8:17 Premerger notification requirements
§ 8:18 Relief—Antitrust Division and Federal Trade Commission
§ 8:19 —Private parties
§ 8:20 Conclusion

CHAPTER 9. ANTITRUST EXEMPTIONS AND IMMUNITIES

§ 9:1 Synopsis and introduction
§ 9:2 Nonprofit entities and noncommercial conduct
§ 9:3 Federal governmental immunity
§ 9:4 Express immunity
§ 9:5 Implied repeal
§ 9:6 Primary and exclusive jurisdiction
§ 9:7 State-action exemption
§ 9:8 Solicitation of government action
§ 9:9 Local Government Antitrust Act
§ 9:10 Business of insurance
§ 9:11 Labor
§ 9:12 Health Care Quality Improvement Act

CHAPTER 10. ENFORCEMENT BY THE ANTITRUST DIVISION AND FEDERAL TRADE COMMISSION

§ 10:1 Introduction

§ 10:2 The Antitrust Division—Organization
§ 10:3 —Criminal enforcement
§ 10:4 —Civil enforcement
§ 10:5 —Relief in civil cases
§ 10:6 —Business review procedure
§ 10:7 The Federal Trade Commission—Organization and authority
§ 10:8 —Investigations and litigation
§ 10:9 —Advisory opinions

CHAPTER 11. PRIVATE ACTIONS UNDER THE ANTITRUST LAWS

§ 11:1 Synopsis and introduction
§ 11:2 Elements of a damage action
§ 11:3 —Injury
§ 11:4 —Business or property
§ 11:5 —Causation
§ 11:6 —Antitrust injury
§ 11:7 —Antitrust standing
§ 11:8 —Damages
§ 11:9 Affirmative defenses
§ 11:10 —Statute of limitations
§ 11:11 —In pari delicto and related defenses
§ 11:12 —Antitrust defenses in nonantitrust cases
§ 11:13 Parties liable
§ 11:14 Effect of government judgments and prior violations
§ 11:15 Injunctive relief

CHAPTER 12. MOTIONS TO DISMISS AND SUMMARY JUDGMENT MOTIONS IN ANTITRUST CASES

§ 12:1 Synopsis and introduction
§ 12:2 Motions to dismiss for failure to state a claim in antitrust cases
§ 12:3 Summary judgment motions in antitrust cases

Table of Contents

PART II. APPLICATION OF ANTITRUST PRINCIPLES TO THE HEALTH CARE SECTOR

CHAPTER 13. PRACTITIONER CREDENTIALING BASED ON PEER REVIEW

§ 13:1 Synopsis and introduction
§ 13:2 Hospital organization and the credentialing process
§ 13:3 Legal theories and parties
§ 13:4 Preliminary issues
§ 13:5 —Interstate commerce
§ 13:6 —State-action exemption
§ 13:7 —Local Government Antitrust Act
§ 13:8 —Health Care Quality Improvement Act
§ 13:9 Antitrust standing
§ 13:10 Analysis under Section 1 of the Sherman Act
§ 13:11 —Capacity to conspire
§ 13:12 —Conspiracy in fact
§ 13:13 —Standard of analysis
§ 13:14 —Analysis under the rule of reason
§ 13:15 — —Relevant market
§ 13:16 — —Effect on competition
§ 13:17 — —Intent and purpose
§ 13:18 Analysis under Section 2 of the Sherman Act
§ 13:19 Allied-Health practitioners
§ 13:20 Discovery in staff-privilege antitrust litigation
§ 13:21 Minimizing antitrust risks

CHAPTER 14. EXCLUSIVE CONTRACTS BETWEEN HOSPITALS AND PHYSICIANS

§ 14:1 Synopsis and introduction

§ 14:2 Antitrust theories
§ 14:3 Hospital-physician exclusive contracts as tying arrangements
§ 14:4 —Separate and distinct products
§ 14:5 —Sale of one service conditioned on purchase of another
§ 14:6 —Market power in the market for the tying product
§ 14:7 —Effect on substantial amount of interstate commerce
§ 14:8 —Economic interest in sale of tied product
§ 14:9 —Legitimate business justification
§ 14:10 Exclusive-dealing agreements
§ 14:11 —Relevant market
§ 14:12 —Effect on competition
§ 14:13 Exclusive contracts as violations of Section 2 of the Sherman Act
§ 14:14 Departmental closings
§ 14:15 Exclusive contracts and vertical price-fixing agreements
§ 14:16 Minimizing antitrust risk

CHAPTER 15. MERGERS IN THE HEALTH CARE SECTOR

§ 15:1 Synopsis and introduction
§ 15:2 Preliminary issues—The economic effects of mergers
§ 15:3 —The relevant federal antitrust statutes
§ 15:4 —Virtual mergers and single-entity status
§ 15:5 —Section 7 and acquisitions by nonprofit entities
§ 15:6 —State-action exemption
§ 15:7 —Interstate commerce
§ 15:8 —Premerger notification, investigation, and preliminary relief
§ 15:9 Analyzing hospital mergers
§ 15:10 —Relevant product market
§ 15:11 —Relevant geographic market
§ 15:12 —Competitor identification and market share calculation
§ 15:13 —Potential harms—Unilateral effects and coordinated effects
§ 15:14 —Unilateral effects

§ 15:15 —Coordinated effects
§ 15:16 —Rebutting the prima facie case
§ 15:17 — —Low entry barriers
§ 15:18 — —Efficiencies
§ 15:19 — —Weakened competitor or "flailing firm"
§ 15:20 — —Failing firm defense
§ 15:21 —Other factors
§ 15:22 — —The Affordable Care Act and health-care reform
§ 15:23 — —Size and sophistication of purchasers
§ 15:24 — —Opinions of purchasers and purchaser complaints
§ 15:25 — —Opinions of competitors and competitor complaints
§ 15:26 — —Party and consultant statements and documents about purpose and effect
§ 15:27 — —Public and private commitments restraining exercise market power
§ 15:28 — —Nonprofit status
§ 15:29 Cross-market and vertical mergers
§ 15:30 Planning a hospital merger—Danger signs—Early counsel involvement
§ 15:31 Other health-care sector mergers
§ 15:32 —Physician practice mergers—Hospital acquisitions of physician practices
§ 15:33 —Health-plan mergers
§ 15:34 —Other health-care sector industry mergers
§ 15:35 State merger notification laws
§ 15:36 FTC frequently asked questions about merger consent order provisions

CHAPTER 16. JOINT VENTURES IN THE HEALTH CARE SECTOR

§ 16:1 Synopsis and introduction
§ 16:2 Definition of joint venture
§ 16:3 Classifications of joint ventures
§ 16:4 Analyzing the joint venture's formation
§ 16:5 Analyzing agreements relating to the joint venture's operation
§ 16:6 Overview of the *Collaboration Guidelines*
§ 16:7 Analyzing particular joint ventures
§ 16:8 —Group purchasing programs

§ 16:9 —Joint ventures among competitors to provide new services, expensive equipment, and specialized services
§ 16:10 —Joint ventures between hospitals and physicians
§ 16:11 Practical factors and danger signals

CHAPTER 17. PROVIDER DIVERSIFICATION

§ 17:1 Synopsis and introduction
§ 17:2 Relevant legal theories
§ 17:3 Diversification and Section 1 of the Sherman Act
§ 17:4 —Diversification resulting from an exclusive dealing agreement
§ 17:5 —Diversification resulting in a tying arrangement
§ 17:6 —Diversification and reciprocal dealing
§ 17:7 Diversification and Section 7 of the Clayton Act
§ 17:8 Diversification and Section 2 of the Sherman Act—Monopolization and attempted monopolization
§ 17:9 —Diversification and predatory refusals to deal
§ 17:10 —Diversification and the essential facilities doctrine
§ 17:11 —Diversification and leveraging
§ 17:12 —Steering as predatory conduct
§ 17:13 Risk minimization in hospital diversification
§ 17:14 Diversification and steering by other providers

CHAPTER 18. COMPETITION BETWEEN HOSPITALS AND PHYSICIAN-OWNED FACILITIES

§ 18:1 Synopsis and introduction
§ 18:2 Issue background
§ 18:3 Actions to combat competition from medical-staff members
§ 18:4 Ethical restraints: Employee non-compete agreements
§ 18:5 Application of antitrust principles

CHAPTER 19. PRICE-FIXING AGREEMENTS AND PRICE AND WAGE EXCHANGES AMONG COMPETITORS

§ 19:1 Synopsis and introduction
§ 19:2 Provider price-fixing agreements, generally
§ 19:3 "Naked" price-fixing agreements
§ 19:4 Forms of provider price-fixing agreements
§ 19:5 Concerted negotiations among providers with payers
§ 19:6 Agreements among competitors to exchange or disseminate pricing information

CHAPTER 20. PROVIDER-CONTROLLED CONTRACTING NETWORKS

§ 20:1 Synopsis and introduction
§ 20:2 Provider-controlled contracting networks
§ 20:3 —Price-fixing agreements
§ 20:4 —Statement 8—Physician network joint ventures
§ 20:5 — —Financial risk sharing and the "antitrust safety zones"
§ 20:6 — —Participation percentages, exclusivity, and the safety zones
§ 20:7 — —Outside the safety zones
§ 20:8 — —Outside the safety zones: Ancillary price-fixing agreements and clinical integration
§ 20:9 — —Physician network joint ventures: Market power
§ 20:10 —Statement 9—Multiprovider networks
§ 20:11 — —Price-fixing agreements in multiprovider networks
§ 20:12 — —Market power in multiprovider networks
§ 20:13 — —Vertical agreements in multiprovider networks
§ 20:14 —Messenger arrangements
§ 20:15 —The Federal Trade Commission and Department of Justice Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program

CHAPTER 21. HEALTH PLAN MARKET POWER AND PROVIDER EXCLUSIONS FROM NETWORKS

§ 21:1 Synopsis and introduction
§ 21:2 Effect of the McCarran-Ferguson Act
§ 21:3 Participation agreements between providers and payers
§ 21:4 Payer monopsony power
§ 21:5 —Payer monopsony power and low reimbursement
§ 21:6 —Payer monopsony power and most-favored-nations provisions
§ 21:7 —Payer monopsony power and all-products provisions
§ 21:8 Exclusion of providers from health plans or contracting networks—Generally
§ 21:9 —Selective and exclusive contracting

CHAPTER 22. MARKET-ALLOCATION AGREEMENTS, HEALTH PLANNING, AND CERTIFICATES OF NEED

§ 22:1 Synopsis and introduction
§ 22:2 The Health Planning Act and the antitrust laws
§ 22:3 CON pros and cons—Agency opposition
§ 22:4 Antitrust ramifications of certificate-of-need proceedings
§ 22:5 Health-planning activities and horizontal market-allocation agreements
§ 22:6 Conclusion

CHAPTER 23. RESALES OF PREFERENTIALLY PRICED COMMODITIES: THE ROBINSON-PATMAN AND NONPROFIT INSTITUTIONS ACTS

§ 23:1 Synopsis and introduction
§ 23:2 Overview of Robinson-Patman Act
§ 23:3 The Non-Profit Institutions Act (NPIA)
§ 23:4 NPIA court decisions
§ 23:5 FTC NPIA advisory opinions

§ 23:6 Practical considerations and principles

CHAPTER 24. ETHICAL RESTRAINTS

§ 24:1 Synopsis and introduction
§ 24:2 Generally applicable antitrust principles
§ 24:3 Ethical restraints: Price-fixing agreements
§ 24:4 Ethical restraints: Agreements not to engage in competitive bidding
§ 24:5 Ethical restraints: Limitations on "poaching"
§ 24:6 Ethical restraints: Limitations on advertising
§ 24:7 Ethical restraints: Restraints on practice form
§ 24:8 Ethical restraints: Membership restrictions
§ 24:9 Ethical restraints: Standards of practice relating to quality
§ 24:10 Conclusion

CHAPTER 25. PAY FOR DELAY AGREEMENTS

§ 25:1 Overview
§ 25:2 Recent pay for delay cases

CHAPTER 26. ANTITRUST IMPLICATIONS AND THE "ORANGE BOOK"

§ 26:1 Antitrust Implications of listing a drug in FDA's "Orange Book" of approved drugs

Table of Laws and Rules

Table of Cases

Index

PART III

APPENDICES

Appendix A

Appendix A. Statutes

Appendix A1. Excerpts from the Sherman Act (15 U.S.C.A. §§ 1 to 8)

Appendix A2. Excerpts from the Clayton Act (15 U.S.C.A. §§ 12, 14 to 27; 29 U.S.C.A. § 52 (2000))

Appendix A3. Excerpts from the Robinson- Patman Act (15 U.S.C.A. §§ 13, 13a, 13b, 21a (2000))

Appendix A4. The Nonprofit Institutions Act (15 U.S.C.A. § 13c (2000))

Appendix A5. Excerpts from the Federal Trade Commission Act (15 U.S.C.A. §§ 41 to 58 (2000))

Appendix A6. The Local Government Antitrust Act (15 U.S.C.A. §§ 34 to 36 (2000))

Appendix A7. The McCarran-Ferguson Act (15 U.S.C.A. §§ 1011 to 1015 (2000))

Appendix A8. The Health Care Quality Improvement Act (42 U.S.C.A. §§ 11101 to 11152 (2000))

Appendix A9. The Antitrust Civil Process Act (15 U.S.C.A. §§ 1311 to 1314 (2000))

Appendix B

Appendix B. Mergers

Appendix B1. 2010 U.S. Department of Justice & Federal Trade Commission Horizontal Merger Guidelines (Aug. 19, 2010)

Appendix B2. Federal Trade Commission Statement Concerning Horizontal Mergers (1982)

Appendix B3. Premerger Notification Form and Instructions Under Amended Section 7A of the Clayton Act

Appendix B3A.	Federal Trade Commission Premerger Notification Office Style Sheet for Hart-Scott-Rodino Filings
Appendix B3B.	Federal Trade Comission Premerger Notification Office Hart-Scott-Rodino Filing Fee Information
Appendix B3C.	U.S. Department of Justice Antitrust Division Merger Review Process Initiative (Oct. 12, 2001)
Appendix B3D	U.S. Department of Justice Antitrust Division Second Request Internal Appeal Procedure (June 2001)
Appendix B3E	Federal Trade Commission Memo to Staff Concerning Merger Investigations (May 16, 2000)
Appendix B3F.	Statement of the Federal Trade Commission's Bureau of Competition on Guidelines for Merger Investigations (Dec. 11, 2002)
Appendix B3G.	Protocol for Coordination in Merger Investigations Between the Federal Enforcement Agencies and State Attorneys General
Appendix B3H	Federal Trade Commission Second-Request Form Letter
Appendix B4.	U.S. Department of Justice Antitrust Division Business Review Procedure
Appendix B5.	Federal Trade Commission Advisory Opinions Procedure
Appendix B6.	1984 U.S. Department of Justice Merger Guidelines
Appendix B7.	Antitrust Division Policy Guide to Merger Remedies
Appendix B8.	Federal Trade Commission Appeal Procedure for Requests for Additional Information
Appendix B9.	DOJ Model Document—Request for Additional Information and Documentary Material Issued to [Weebyewe Corporation] (February 2021)

Appendix B10. Model Order to File Special Report Regarding Physician Group and Healthcare Facility Mergers (January 2021)

Appendix B11. DOJ Antitrust Division Updated Guidance Regarding the Use of Arbitration and Case Selection Criteria

Appendix B12. FTC's The Most Frequently Asked HSR Questions

Appendix B13. FTC Tips on Withdrawing and Refiling an HSR Premerger Notification Filing

Appendix B14. Washington AG Guidance on Healthcare Transactions Notification Requirement

Appendix B15. US GAO Report - Federal Antitrust Policy: Stakeholders' Perspectives Differed on the Adequacy of Guidance for Collaboration among Health Care Providers

Appendix B16. FTC Announcement: The Treatment of Debt as Consideration (regarding HSR Act's notification requirements) (August 26, 2021)

Appendix B17. FTC Announcement: Statement of the Commission on the Use of Prior Approval Provisions in Merger Orders (October 25, 2021)

Appendix B18. Sample FTC Proposed Order in *In re Davita, et al* case illustrating re-instituted use of Prior Approval Provisions in merger orders

Appendix B19. Federal Trade Commission and Justice Department Seek to Strengthen Enforcement Against Illegal Mergers (Press release - January 18, 2022)

Appendix B20. 2023 DOJ and FTC Merger Guidelines (December 18, 2023)

Appendix B21. FTC Press Release: FTC, DOJ and HHS Work to Lower Health Care and Drug Costs, Promote Competition to Benefit Patients, Health Care Workers (December 7, 2023)

Appendix B22. Federal Trade Commission Statement Concerning Brand Drug Manufacturers' Improper Listing of Patents in the Orange Book (September 14, 2023)

Appendix B23. Deputy Attorney General Lisa O. Monaco Announces New Safe Harbor Policy for Voluntary Self-Disclosures Made in Connection with Mergers and Acquisitions (October 4, 2023)

Appendix B24. Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter In the Matter of Sanofi/ Maze Therapeutics (December 20, 2023)

Appendix B25. FTC Statement on Second Circuit Order Upholding "Pharma Bro" Martin Shkreli's Lifetime Ban (January 23, 2024)

Appendix B26. Revised Jurisdictional Thresholds for Section 7A of the Clayton Act for Hart-Scott-Rodino Premerger Notification Filings (January 2024)

Appendix C

Appendix C. Business Review Letters: Department of Justice

Appendix C1. Business Review Letter to Gales Rexall Drug (Nov. 17, 1975)

Appendix C2. Business Review Letter to California Pharmaceutical Association (Sept. 30, 1976)

Appendix C3. Business Review Letter to International Chiropractors Association (March 2, 1977)

Appendix C4. Business Review Letter Relating to Wisconsin Rate Review Program (July 5, 1977)

Appendix C5. Business Review Letter to American Hospital Association (June 12, 1978)

Appendix C6. Business Review Letter to Morros & Associates (Aug. 14, 1978)

Appendix C7. Business Review Letter to American Medical Association (March 9, 1979)

Appendix C8. Business Review Letter to American Association of Ophthalmology (July 3, 1979)

Appendix C9. Business Review Letter to Central Virginia Health Systems Agency (May 8, 1980)

Appendix C10. Business Review Letter to Westlake Health Campus Association (Aug. 27, 1980)

Appendix C11. Business Review Letter to Maryland Health Care Coalition (Feb. 19, 1982)

Appendix C12. Business Review Letter to Southwestern Michigan Health Systems Agency (March 2, 1982)

Appendix C13. Business Review Letter to Ohio Hospital Purchasing Consortium (June 9, 1982)

Appendix C14. Business Review Letter to Health Care Management Associates (Sept. 21, 1983)

Appendix C15. Business Review Letter to Hospital Corporation of America (Sept. 21, 1983)

Appendix C16. Business Review Letter to Stark County Health Care Coalition (Aug. 30, 1985)

Appendix C17. Business Review Letter to Lexecon Health Service (June 20, 1986)

Appendix C18. Business Review Letter to Pharmaceutical Care Network (Oct. 3, 1986)

Appendix C19. Business Review Letter to Service For You (Oct. 3, 1986)

Appendix C20. Antitrust Division Letter to American Medical Association (Dec. 2, 1986)

Appendix C21. Business Review Letter to American Red Cross (Dec. 12, 1986)

Appendix C22. Business Review Letter to North Mississippi Health Services (April 9, 1987)

Appendix C23. Business Review Letter to Independent

Drug Wholesalers Group (May 18, 1987)

Appendix C24. Business Review Letter to Danbury Surgical Associates (Aug. 28, 1987)

Appendix C25. Business Review Letter to St. Louis Area Business Health Coalition (March 24, 1988)

Appendix C26. Business Review Letter to Baxter Healthcare Corporation (July 29, 1988)

Appendix C27. Business Review Letter to American Heart Association (April 28, 1989)

Appendix C28. Business Review Letter to Hyatt Imler Ott & Blount, P.C. (June 12, 1992)

Appendix C29. Business Review Letter to Transplant Associates (Oct. 26, 1992)

Appendix C30. Business Review Letter to Case Western Reserve University School of Medicine (Jan. 7, 1993)

Appendix C31. Department of Justice Advisory Letter to the Pennsylvania Insurance Commissioner (Sept. 7, 1993)

Appendix C32. Business Review Letter to National Cardiovascular Network, Inc. (Sept. 28, 1993)

Appendix C33. Business Review Letter to Pharmaceutical Manufacturers Association (Oct. 1, 1993)

Appendix C34. Business Review Letter to the Health and Personal Care Distribution Conference, Inc. (Oct. 13, 1993)

Appendix C35. Business Review Letter to St. Anthony Medical Center (Nov. 8, 1993)

Appendix C36. Business Review Letter to California Chiropractic Association (Dec. 8, 1993)

Appendix C37. Business Review Letter to Bay Area Business Group on Health (Feb. 18, 1994)

Appendix C38. Business Review Letter to New Jersey Hospital Association (Feb. 18, 1994)

Appendix C39. Business Review Letter to Houston Health Care Coalition (Mar. 23, 1994)

Appendix C40. Department of Justice Advisory Letter to Sen. Howard Metzenbaum (Apr. 14, 1994)

Appendix C41. Business Review Letter to Hotel Employees and Restaurant Employees International Union Welfare Fund (May 20, 1994)

Appendix C42. Business Review Letter to Birmingham Cooperative Clinical Benchmarking Demonstration Project (June 20, 1994)

Appendix C43. Business Review Letter to Seeskin, Paas, Blackburn & Co. (June 29, 1994)

Appendix C44. Business Review Letter to Des Moines Collaborative Provider Organization, Inc. (July 6, 1994)

Appendix C45. Business Review Letter to Preferred Podiatric Network Inc. and the New York State Podiatric Medical Association (Sept. 14, 1994)

Appendix C46. Business Review Letter to International Chiropractor's Association of California (Oct. 27, 1994)

Appendix C47. Business Review Letter to Physician Care, Inc. (Oct. 28, 1994)

Appendix C48. Business Review Letter to Pulmonary Associates, Ltd., and Albuquerque Pulmonary Consultants, P.A. (Oct. 31, 1994)

Appendix C49. Business Review Letter to Chicagoland Radiological Network (Dec. 8, 1994)

Appendix C50. Business Review Letter to Northwestern National Life Insurance Company (March 9, 1995)

Appendix C51. Business Review Letter to Hillhaven Corp. (March 29, 1995)

Appendix C52. Business Review Letter to Mid-South Health Plan (March 30, 1995)

Appendix C53. Business Review Letter to AdviNet, Inc. (May 12, 1995)

Appendix C54. Business Review Letter to Pennsylvania Orthotics & Prosthetics Enterprise (July 17, 1995)

Appendix C55. Business Review Letter to Hanger Orthopedic Group, Inc. (Sept. 15, 1995)

Appendix C56. Business Review Letter to Dr. Oswald L. Mikell Regarding Proposed Network of Dermatologists (Nov. 1, 1995)

Appendix C57. Business Review Letter to Southwest Oncology Group (Nov. 2, 1995)

Appendix C58. Business Review Letter to Georgia Preferred Podiatric Medical Network (Nov. 3, 1995)

Appendix C59. Business Review Letter to Dermnet, Inc. (Dec. 5, 1995)

Appendix C60. Business Review Letter to Preferred Laboratory Access Network (Dec. 7, 1995)

Appendix C61. Business Review Letter to Oklahoma Physicians Network–IPA, Inc. and PROklahoma Care, Inc. (Jan. 17, 1996)

Appendix C62. Business Review Letter to Children's Healthcare, P.A. (March 1, 1996)

Appendix C63. Business Review Leter to Southern Health Corporation (March 5, 1996)

Appendix C64. Business Review Letter to Orange Los Angeles Medical Group, Inc. (March 8, 1996)

Appendix C65. Business Review Letter to Itasca Clinic and Grand Rapids Medical Associates (March 19, 1996)

Appendix C66. Business Review Letter to Allergy & Asthma Consultants, Inc. (March 19, 1996)

Appendix C67. Business Review Letter to Hospice Network of New Jersey, Inc. (April 24, 1996)

Appendix C68. Business Review Letter to Plastic Surgery Associates of Connecticut, LLC (June 28, 1996)

Appendix C69. Business Review Letter to Allied Colon and Rectal Specialists (July 1, 1996)

Appendix C70. Business Review Letter Primary and Specialist Medical Center, L.L.C. (July 2, 1996)

Appendix C71. Business Review Letter to El Paso Surgical Group (July 24, 1996)

Appendix C72. Business Review Letter to Sierra CommCare, Inc. (Aug. 15, 1996)

Appendix C73. Business Review Letter to Home Care Alliance, Inc. (Oct. 4, 1996)

Appendix C74. Business Review Letter to Cincinnati Regional Orthopaedic and Sports Medicine Associates, Inc. (CROSMA) (Oct. 4, 1996)

Appendix C75. Business Review Letter to Terence L. Smith, M.D. (Oct. 17, 1996)

Appendix C76. Business Review Letter to RWHC Network, Inc. (Nov. 12, 1996)

Appendix C77. Business Review Letter to Marin General Hospital and Ross Hospital (Feb. 11, 1997)

Appendix C78. Business Review Letter to Sante Fe, New Mexico Managed Care Organization (Feb. 12, 1997)

Appendix C79. Business Review Letter to Orthopaedic Associates of Mobile, P.A., and Bone & Joint Center of Mobile (Apr. 16, 1997)

Appendix C80. Business Review Letter to CVT Surgical Center and Vascular Surgery Associates of Baton Rouge (Apr. 16, 1997)

Appendix C81. Business Review Letter to Southwest Orthopedic Specialists (June 10, 1997)

Appendix C82. Business Review Letter to Gastroenterology Associates, Ltd.; GI Associates, P.C.; and Valley Gastroenterologists (July 7, 1997)

Appendix C83. Business Review Letter to Vermont Physicians Clinic (July 30, 1997)

Appendix C84. Business Review Letter to First Priority Health (Nov. 3, 1997)

Appendix C85. Business Review Letter to the American Heart Association Pharmaceutical Roundtable (Mar. 20, 1998)

Appendix C86. Business Review Letter to the Heritage Alliance and Lackawanna Physicians Organization (Sept. 15, 1998)

Appendix C87. Business Review Letter to Santa Fe, New Mexico Managed Care Organization (Sept. 16, 1998)

Appendix C88. Business Review Letter to NSM Purchasing Association (Jan. 13, 1999)

Appendix C89. Business Review Letter to Preferred Physicians Medical Group (July 23, 1999)

Appendix C90. Antitrust Division Business Review Letter to Midwest Behavorial Health LLC (Feb. 4, 2000)

Appendix C91. Business Review Letter to Rio Grande Eye Associates, P.A. (Aug. 29, 2001)

Appendix C92. Business Review Letter to Olympus America, Inc. (Aug. 29, 2001)

Appendix C93. Business Review Letter to Michigan Hospital Group, Inc. (April 2, 2002)

Appendix C94. Business Review Letter to Washington State Medical Association (Sept. 23, 2002)

Appendix C95. Business Review Letter to Linen Systems for Healthcare, LLC (Aug. 8, 2006)

Appendix C96. Business Review Letter to Diana West (May 25, 2004)

Appendix C97. Letter from Mark J. Botti, Chief, Litigation I Section, Antitrust Division, to the South Carolina State Health Planning Committee Concerning Certificate-of-Need Regulation (Dec. 8, 2006)

Appendix C98. Letter from Joseph Miller, Assistant Chief, Litigation I Section, Antitrust Division, to Sen. Michael D. Bishop, Michigan Senate Majority Leader, Concerning Proposed Standards of the Michigan Certificate of Need Commission

Appendix C99. Business Review Letter to the CEO Roundtable on Cancer (Sept. 28, 2008)

Appendix C100. Business Review Letter to Memorial Health, Inc., and St. Joseph's/Candler Health System (Sept. 4, 2009)

Appendix C101. Business Review Letter to Pacific Business Group on Health Concerning Reimbursement and Quality Information Dissemination Program (Apr. 26, 2010)

Appendix C102. Business Review Letter to the Greater New York Hospital Association Concerning Hospital Gainsharing Program

Appendix C103. Antitrust Division Advocacy Letter to Sen. Peter MacGregor, Michigan State Senate Concerning Legislation Addressing Telehealth Services (Nov. 29, 2016)

Appendix C104. Business review letter to McKesson Corporation ("McKesson"), Cardinal Health, Inc. ("Cardinal"), Owens & Minor, Inc. ("OMI"), Medline Industries, Inc. ("Medline"), and Henry Schein, Inc. ("Henry Schein") relating to collaboration among distributors of personal-protective equipment ("PPE"), oxygen, and medications (April 4, 2020)

Appendix C105. Baxalta, Emergent BioSolutions, Grifols Therapeutics, and CSL Plasma Expedited Business Review Letter (January 12, 2021)

Appendix C106. Eli Lilly and Company, AbCellera Biologics, Amgen, AstraZeneca,

Genentech, and GSK Expedited Business Review Request Pursuant to COVID-19 Expedited Procedure (July 23, 2020)

Appendix C107. DOJ Antitrust Division Summary of Business Reviews (Since 1993 Issuance of DOJ/FTC Health Care Antitrust Statement of Enforcement Policy)

Appendix D

Appendix D. Advisory Opinions: Federal Trade Commission Staff

Appendix D1. FTC Statement Regarding Physician Agreements to Control Medical Prepayment Plans (Oct. 5, 1981)

Appendix D2. FTC Staff Advisory Opinion to Louisiana Health Care Association (April 23, 1982)

Appendix D3. FTC Staff Advisory Opinion to Health Care Management Associates (June 7, 1983) (101 F.T.C. 1014)

Appendix D4. FTC Staff Advisory Opinion to American Podiatry Association (Aug. 18, 1983)

Appendix D5. FTC Staff Advisory Opinion to North Carolina Chiropractic Association (Feb. 29, 1984)

Appendix D6. FTC Staff Advisory Opinion to Medical Society of the County of Erie (March 12, 1984)

Appendix D7. FTC Staff Advisory Opinion to American Podiatry Association (March 13, 1984)

Appendix D8. FTC Staff Advisory Opinion to Gilbert M. Frimet (March 22, 1984)

Appendix D9. FTC Staff Advisory Opinion to Kitsap Physicians Service (March 26, 1984)

Appendix D10. FTC Staff Advisory Opinion to Peer Review Organizations of Ohio Foundation (April 26, 1984)

Appendix D11. FTC Staff Advisory Opinion to Kitsap Physicians Service (May 22, 1984)

Appendix D12. FTC Staff Advisory Opinion to Tarrant County Medical Society (May 25, 1984)

Appendix D13. FTC Staff Advisory Opinion to Tarrant County Medical Society (July 11, 1984)

Appendix D14. FTC Staff Advisory Opinion to Utah Society of Oral and Maxillofacial Surgeons (Feb. 8, 1985)

Appendix D15. FTC Staff Advisory Opinion to American Dental Association (Aug. 26, 1985)

Appendix D16. FTC Staff Advisory Opinion to Private Healthcare Systems (Sept. 24, 1985)

Appendix D17. FTC Staff Advisory Opinion to American Intra-Ocular Implant Society (Oct. 11, 1985)

Appendix D18. FTC Staff Advisory Opinion to North Texas Chapter, American College of Surgeons (Dec. 12, 1985)

Appendix D19. FTC Staff Advisory Opinion to Passaic County Medical Society (Jan. 3, 1986)

Appendix D20. FTC Staff Advisory Opinion to Michael A. Duncheon (March 17, 1986)

Appendix D21. FTC Staff Advisory Opinion to the Equitable Life Assurance Society of the United States (March 26, 1986)

Appendix D22. FTC Staff Advisory Opinion to Association of Quality Health Care (Aug. 28, 1986)

Appendix D23. FTC Staff Advisory Opinion to Pacific International Health (Aug. 28, 1986)

Appendix D24. FTC Views on HMO Exclusive Contracts (Nov. 5, 1986)

Appendix D25. FTC Staff Advisory Opinion to Maryland Medical Eye Associates (May 15, 1987)

Appendix D26. FTC Staff Advisory Opinion to Intracorp (March 25, 1988)

Appendix D27. FTC Staff Advisory Opinion to Pan

American Management Associates (June 27, 1989)

Appendix D28. FTC Staff Advisory Opinion to American Dental Association (Feb. 15, 1990)

Appendix D29. FTC Staff Advisory Opinion to Wichita, Kansas, Chamber of Commerce

Appendix D30. FTC Staff Advisory Opinion to the National Capital Society of Plastic and Reconstructive Surgeons (April 23, 1991)

Appendix D31. FTC Staff Advisory Opinion to a Physician IPA That Sponsors a PPO (June 20, 1991)

Appendix D32. FTC Letter to the New Hampshire Senate Regarding "Any-Willing-Provider" Laws (Mar. 17, 1992)

Appendix D33. FTC Letter to the California Senate Regarding "Any-Willing Provider" Laws (June 26, 1992)

Appendix D34. FTC Staff Letter to the Montana House of Representatives Involving Denturists (Oct. 30, 1992)

Appendix D35. FTC Staff Letter to Missouri Board of Chiropractic Examiners Regarding Free or Discounted Services (Dec. 11, 1992)

Appendix D36. FTC Staff Letter to the Attorney General of Montana Regarding "Any-Willing-Provider" Laws (Feb. 4, 1993)

Appendix D37. FTC Staff Letter to the Attorney General of North Dakota Regarding Cooperative Arrangements Among Hospitals and "Certificate-of-Public-Advantage" Law (Mar. 8, 1993)

Appendix D38. FTC Letter to Sen. Orrin G. Hatch Regarding Hospital Mergers (June 8, 1993)

Appendix D39. FTC Staff Advisory Opinion to California Managed Imaging Medical Group, Inc. (Nov. 17, 1993)

Appendix D40. FTC Advisory Opinion to Presentation Health System (Dec. 21, 1993)

Appendix D41. FTC Advisory Opinion to American Medical Association and Chicago Medical Society (Feb. 14, 1994)

Appendix D42. FTC Letter from Michael D. McNeely, Assistant Director, Bureau of Competition, Federal Trade Commission, to Clifton E. Johnson (June 13, 1994)

Appendix D43. FTC Staff Advisory Opinion to ACMG, Inc. (July 5, 1994)

Appendix D44. FTC Staff Advisory Opinion to Southeast Managed Care, Inc. (July 5, 1994)

Appendix D45. FTC Letter to Suffolk County Dental Society (July 6, 1994)

Appendix D46. FTC Staff Advisory Opinion to Palmetto Dental Alliance (Sept. 23, 1994)

Appendix D47. FTC Staff Advisory Opinion to Rocky Mountain Cardiovascular Affiliates (Sept. 23, 1994)

Appendix D48. FTC Staff Advisory Opinion to Oakland Physician Network (March 28, 1995)

Appendix D49. FTC Staff Advisory Opinion to Erlanger Medical Center and Memorial Hospital (May 31, 1995)

Appendix D50. FTC Staff Advisory Opinion to California All Health (June 14, 1995)

Appendix D51. FTC Staff Advisory Opinion to Elmore Community Hospital and Community Hospital (June 20, 1995)

Appendix D52. FTC Staff Advisory Opinion to Northwestern Nevada Orthopaedic Surgery Alliance (July 11, 1995)

Appendix D53. FTC Staff Advisory Opinion to Otolaryngology Specialty Providers of Georgia (Aug. 15, 1995)

Appendix D54. FTC Staff Advisory Opinion to Hematology/Oncology Care Specialists of Western Pennsylvania, P.C. (Sept. 21, 1995)

Appendix D55. FTC Staff Advisory Opinion to Eastern Ohio Physicians Organization, Inc. (Sept. 28, 1995)

Appendix D56. FTC Staff Advisory Opinion to Central Texas Medical Group (Sept. 28, 1995)

Appendix D57. FTC Staff Advisory Opinion to Columbine Family Health Center (Nov. 8, 1995)

Appendix D58. FTC Staff Advisory Opinion to Southern Arizona Therapy Network, Inc. (Dec. 7, 1995)

Appendix D59. FTC Staff Advisory Opinion to URONET of Louisiana, L.L.C. (Jan. 23, 1996)

Appendix D60. FTC Staff Advisory Opinion to the American Medical Association (March 26, 1996)

Appendix D61. Appendix D63-FTC Staff Advisory Opinion to Mayo Medical Laboratories (July 17, 1996)

Appendix D62. FTC Staff Advisory Opinion to William W. Backus Hospital (June 11, 1996)

Appendix D63. FTC Letter to Columbus Hospital and Montana Deaconess Medical Center (June 28, 1996)

Appendix D64. FTC Staff Advisory Opinion to Business Health Companies (Oct. 19, 1996)

Appendix D65. FTC Staff Advisory Opinion to Southwest Florida Oral Surgery Associates (Dec. 2, 1996)

Appendix D66. FTC Staff Advisory Opinion to Ohio Ambulance Network, Inc. (Jan. 23, 1997)

Appendix D67. FTC Staff Advisory Opinion to Mobile Health Resources, L.L.C. (Jan. 23, 1997)

Appendix D68. FTC Staff Advisory Opinion to Valley Baptist Medical Center (Sept. 19, 1996)

Appendix D69. FTC Staff Advisory Opinion to North Mississippi Health Services (Oct. 3, 1996)

Appendix D70. FTC Staff Advisory Opinion to Business Health Companies, Inc. (Oct. 18, 1996)

Appendix D71. FTC Staff Advisory Opinion to North Ottawa Community Hospital (Oct. 22, 1996)

Appendix D72. FTC Staff Advisory Opinion to Foundation for the Accreditation of Hematopoietic Cell Therapy (Apr. 17, 1997)

Appendix D73. FTC Staff Advisory Opinion to Yellowstone Physicians, L.L.C. (May 14, 1997)

Appendix D74. FTC Staff Advisory Opinion to Henry County Memorial Hospital (Apr. 10, 1997)

Appendix D75. FTC Staff Advisory Opinion to First Look, L.L.C. (June 19, 1997)

Appendix D76. FTC Staff Advisory Opinion to New Jersey Pharmacists Association (Aug. 12, 1997)

Appendix D76A. FTC Staff Advisory Opinion to Mesa County Physicians Independent Practice Association (Nov. 6, 1997)

Appendix D77. FTC Staff Advisory Opinion to Community Hospital, Inc. (Dec. 22, 1997)

Appendix D78. FTC Staff Advisory Opinion to the Alliance of Independent Medical Services, LLC (Dec. 22, 1997)

Appendix D79. FTC Staff Advisory Opinion to North Mississippi Health Services (Jan. 7, 1998)

Appendix D80. FTC Staff Advisory Opinion to Phoenix Medical Network, Inc. (May 19, 1998)

Appendix D81. FTC Staff Advisory Opinion to Associates in Neurology (Aug. 13, 1998)

Appendix D82. FTC Staff Advisory Opinion to Wesley Health Center, Inc. (April 29, 1999)

Appendix D83. FTC Letter to Texas House of

Representatives Concerning Joint Negotiations by Physicians (May 13, 1999)

Appendix D84. FTC Staff Advisory Opinion to Orange Pharmacy Equitable Network (May 19, 1999)

Appendix D85. FTC Staff Advisory Opinion to BJC Health System (Nov. 9, 1999)

Appendix D86. FTC Staff Letter to the District of Columbia Corporation Counsel Concerning Physician Joint-Negogiation Statute (Oct. 29, 1999)

Appendix D87. FTC Staff Advisory Opinion to Northeast Pharmacy Service Corporation (July 27, 2000)

Appendix D88. FTC Staff Advisory Opinion to Havard Vanguard Medical Associates, Inc. (Dec. 18, 2001)

PART III

APPENDICES

Appendix D

Appendix D89. FTC Staff Advisory Opinion to the Connecticut Hospital Association (Dec. 20, 2001)

Appendix D90. FTC Staff Letter to Alaska House of Representatives Concerning Physician Joint Negotiation Statute (Jan. 18, 2002)

Appendix D91. FTC Staff Letter to State of Washington House of Representatives Concerning Physician Joint Negotiation Statute (Feb. 8, 2002)

Appendix D92. FTC Staff Advisory Opinion to MedSouth, Inc. (Feb. 19, 2002)

Appendix D93. Letter from Joseph J. Simons, Director, Jeffrey W. Brennan, Assistant Director and R. Ted Cruz, Attorney, Federal Trade Commission, to Honorable Dennis Stapleton, Chairman, Insurance Committee, Ohio House of Representatives, relating to legislative exemption for physician collective bargaining (Oct. 16, 2002)

Appendix D94. FTC Staff Advisory Opinion to Viquest and Pitt Country Memorial Hospital (Mar. 8, 2002)

Appendix D95. FTC Staff Letter to Ohio House of Representatives (Oct. 16, 2002)

Appendix D96. FTC Staff Advisory Opinion to PriMed Physicians (Feb. 6, 2003)

Appendix D97. FTC Staff Advisory Opinion to Valley Baptist Medical Center (March 13, 2003)

Appendix D98. FTC Staff Advisory Opinion to Arkansas Children's Hospital (March 13, 2003)

Appendix D99. FTC Staff Letter to the Louisiana Attorney General Concerning Tenet Healthcare Corporation's Proposed Acquisition of Sliddell Memorial Hospital (Apr. 1, 2003)

Appendix D100. FTC Staff Letter to the Tennessee Senate Concerning Bill Regulating Optometry (Apr. 29, 2003)

Appendix D101. FTC Staff Advisory Opinon to Medical Group Management Association (Nov. 3, 2003)

Appendix D102. FTC Staff Advisory Opinion to Bay Area Preferred Physicians (Sept. 23, 2003)

Appendix D103. FTC Staff Advisory Opinion to Dunlap Memorial Hospital (Jan. 6, 1004)

Appendix D104. FTC Staff Letter to Patrick C. Lynch, Attorney General of Rhode Island (Apr. 8, 2004)

Appendix D105. FTC Letter to North Dakota Senate re PBM Contractual Relationships (March 8, 2005)

Appendix D106. Letter to Delegate Purkey Regarding Virginia House Bills 2518 and 160 and Virginia Senate Bill 272 re Optometric Care (March 9, 2005)

Appendix D107. Staff Advisory Opinion to Stevens Hospital (Apr. 18, 2005)

Appendix D108. FTC Staff Letter to Rep. Patrick McHenry Concerning Proposed Bill Regulating Pharmacy Benefit Manager Contractual Relationships (July 15, 2005)

Appendix D109. FTC Staff Advisory Opinion to North Mississippi Health Services (Aug. 16, 2005)

Appendix D110. FTC Staff Advisory Opinion to Suburban Health Organization, Inc. (Mar. 28, 2006)

Appendix D111. FTC Staff Advisory Opinion to Alpena Public Schools (June 16, 2006)

Appendix D112. FTC Staff Advisory Opinion to St. John's Health System (Sept. 13, 2006)

Appendix D113. Letter from FTC Directors to Terry G. Kilgore, Virginia House of Delegates, Concerning PBM Regulation (Oct. 2, 2006)

Appendix D114. FTC Bureau of Competition and Bureau of Economics Letter to Nellie Pou, Assemblywoman, New Jersey General Assembly, concerning regulation of pharmacy benefit managers (Apr. 17, 2007)

Appendix D115. FTC Staff Follow-Up Letter to MedSouth, Inc. (June 18, 2007)

Appendix D116. FTC Staff Advisory Opinion to Greater Rochester Independent Practice Association (Sept. 17, 2007)

Appendix D117. FTC Staff Letter to Massachusetts Department of Public Health Concerning Clinic Advertising

Appendix D118. FTC Staff Letter to Puerto Rico Treasury and Financial Affairs Committee (Jan. 30, 2008) (objecting to bill permitting health-care providers to collectively negotiate fees)

Appendix D119. FTC Staff Advisory Opinion to Kaiser Foundation Health Plan (Feb. 13, 2008)

Appendix D120. FTC Staff Letter to Hon. William J. Seitz, Ohio State Senator, Concerning Collective Bargaining by Home Care Providers (Feb. 14, 2008)

Appendix D121. Letter from Maureen K. Ohlhausen, Director, Office of Policy Planning, Michael R. Baye, Director, Bureau of Economics, Jeffrey Schmidt, Director, Bureau of Competition, and Lydia B. Parnes, Director, Bureau of Consumer Protection, FTC, to Hon. Elaine Nekritz, Illinois State Representative, Concerning Proposed Regulation of Retail Health Care Facilities

Appendix D122. FTC Staff Letter to Rep. Tom Emmer, Minnesota House of Representatives, Concerning Rural Health Care Cooperative Joint Negotiations (Mar. 18, 2009)

Appendix D123. FTC Staff Letter to Hon. James L. Seward, Senator, New York Senate, Concerning Pharmacy-Benefit-Manager Regulation (Mar. 31, 2009)

Appendix D124. FTC Staff Opinion Letter to TriState Health Partners (Apr. 13, 2009)

Appendix D125. FTC Staff Letter to Hon. Timothy G. Burns, Louisiana House of Representatives, Concerning In-School Dentistry Regulation (May 1, 2009)

Appendix D126. FTC Staff Comments to the Louisiana State Board of Dentistry Regarding Proposed Modifications to Louisiana Rules Regarding the Practice of Portable and Mobile Dentistry (Dec. 9, 2009)

Appendix D127. FTC Staff Advisory Opinion to the University of Michigan Concerning Non-Profit Institutions Act

Appendix D128. FTC Staff Advisory opinion to Community CarePartners (Non-Profit Institutions Act) (July 2, 2010)

Appendix D129. FTC Staff Comments to the Kentucky Cabinet for Health and Family Services Concerning Proposed Rule to Regulate Limited Service Clinics (Jan. 28, 2010)

Appendix D130. FTC Staff Comments to the Alabama State Board of Medical Examiners Concerning Proposed Regulation of Interventional Pain Management Services (Nov. 3, 2010)

Appendix D131. FTC Staff Comments to the Georgia Board of Dentistry Concerning Proposed Amendments to Rules Governing Supervision of Dental Hygienists (Dec. 30, 2010)

Appendix D132. FTC Staff Comments to the North Carolina State Board of Opticians Concerning Proposed Regulations for Optical Goods and Optical Goods Businesses (Jan. 13, 2011)

Appendix D133. Letter from J. Thomas Rosch, Commissioner, FTC, to Donald M. Berwick and Nancy-Ann DeParle Concerning the Antitrust Ramifications of Accountable Care Organizations (Jan. 24, 2011)

Appendix D134. Letter from Certain U.S. Senators to Christine Varney, Assistant Attorney General, Antitrust Division, and Jon Leibowitz, Chairman, FTC, Concerning Antitrust and Accountable Care Organizations

Appendix D135. FTC Staff Letter to Hon. Daphne Campbell, Florida House of Representatives Concerning Regulation of Advanced Registered Nurse Practitioners (Mar. 22, 2010)

Appendix D136. FTC Staff Letter to Hon. Mark Formby, Mississippi House of Representatives, Concerning Regulation of Pharmacy Benefit Managers (Mar. 22, 2011)

Appendix D137. FTC Staff Letter to Sens. Rodney Ellis and Royce West, Texas State Senate, Concerning Regulation of Advanced Practice Registered Nurses (May 11, 2011)

Appendix D138. FTC Staff Letter to Rep. Elliott Naishat, Texas House of Representative, Concerning Bill to Permit Health Care Collaboratives (May 18, 2011)

Appendix D139. Antitrust Division Staff Letter to Rep. Phillip Johnson, Tennessee Legislature Concerning Repeal of State-Action Exemption Legislation for Tennessee Public Hospitals (May 18, 2011)

Appendix D140. FTC Staff Letter to Members of the

Connecticut General Assembly Concerning a Bill to Establish Provider Cooperative Care Arrangements (June 8, 2011)

Appendix D141. FTC Staff Comments to Sen. James L. Seward, New York State, Regarding Regulation of Mail-Order Pharmacies (Aug. 8, 2011)

Appendix D142. FTC Staff Letter to Hon. Gary Odom, Tennessee House of Representatives, Concerning a Bill to Regulate Pain Management Services (Sept. 28, 2011)

Appendix D143. FTC Staff Letter to Sen. John Bonacic, New York State Senate, Concerning a Bill to Permit Collective Negotiations Among Providers (Oct. 20, 2011)

Appendix D144. FTC Staff Letter to Teneale Johnson, Maine Board of Dental Examiners, Concerning Proposed Rule to Limit X-Ray Procedures by Dental Hygienists (Nov. 16, 2011)

Appendix D145. FTC Staff Letter to Hon. Paul Hornback, Kentucky State Senate, Concerning a Bill Relating to Advanced Practice Registered Nurses Scope of Practice (Mar. 26, 2012)

Appendix D146. FTC Staff Letter to Hon. Jeanne Kirkton, Missouri House of Representatives, Concerning a Bill Relating to CRNA Scope of Practice (Mar. 27, 2012)

Appendix D147. FTC Staff Letter to Hon. Thomas P. Willmott and Hon. Patrick C. Williams, Louisiana State Representatives Concerning Advance Practice Registered Nurse Collaborative Agreements (Apr. 20, 2012)

Appendix D148. FTC Staff Letter to Hon. Stephen LaRoque, North Carolina House of Representatives, Concerning Dental Practice Managers (May 25, 2012)

Appendix D149. FTC Staff Advisory Opinion to Generic

Pharmaceutical Association (Aug. 8, 2012)

Appendix D150. FTC Staff Advisory Opinion to Yakima Valley Memorial Hospital Re: Application of Non-Profit Institutions Act

Appendix D151. FTC Staff Advisory Opinion to the Methodist Hospital System Concerning Application of Non-Proft Institutions Act (Nov. 30, 2012)

Appendix D152. FTC Staff Advisory Opinion to Norman Physician Hospital Organization (Feb. 13, 2013)

Appendix D153. FTC Staff Advocacy Letter to Hon. Theresa W. Conroy, Connecticut State Representative, Concerning Advanced Practice Registered Nurses (Mar. 19, 2013)

Appendix D154. FTC Staff Letter to Hon. Heather A Steans, Illinois State Senate, Concerning Proposed Legislation Limiting Chronic Pain Treatment by Certified Registered Nurse Anesthetists

Appendix D155. FTC Staff Letter to Hon. Catherine Osten, Connecticut General Assembly Concerning Proposed Legislation for Physician Collaboration (June 4, 2013)

Appendix D156. FTC Staff Letter to the Commission on Dental Accreditation Concerning Accreditation of Dental Therapists (Dec. 2, 2013)

Appendix D157. FTC Staff Letter to Hon. Kay Khan, Massachusetts House of Representatives, Concerning Bill to Remove Supervision Requirements from Nurse Practitioners and Nurse Anesthesiologists (Jan. 17, 2014)

Appendix D158. FTC Staff Advocacy Letter to Sherin Tooks, Commission on Dental Accreditation, Concerning Accreditation Standards for Dental Therapy Education (Dec. 2, 2013)

Appendix D159. FTC Staff Advocacy Letter to Centers for Medicare and Medicaid Services Concerning Any-Willing-Provider Changes to Medicare Prescription Drug Benefit Programs (Mar. 7, 2014)

Appendix D160. FTC Staff Advisory Opinion to Quest Analytics Group Concerning the Non-Profit Institutions Act (Mar. 7, 2014)

Appendix D161. FTC Staff Advocacy Letter to Simone Salloum, Texas State Board of Dental Examiners, Concerning Proposed Rules (Oct. 14, 2014)

Appendix D162. FTC Staff Advocacy Letter to Sherin Tooks, Commission on Dental Accreditation, Concerning Accreditation Standards for Dental Therapy Education (Dec. 12, 1014)

Appendix D163. FTC Staff Advocacy Letter to Department of Health & Human Services Concerning Interoperability of Health Information Technology (Apr. 3, 2015)

Appendix D164. FTC Staff Advocacy Letter to Hon. Jeanne Kirkton, Missouri House of Representatives, Concerning Bill to Remove Advanced Practice Registered Nurse Practice Restrictions (Apr. 21, 2015)

Appendix D165. FTC Staff Advocacy Letter to the New York State Department of Health Concerning Certificates of Public Advantage (Apr. 22, 2015)

Appendix D166. FTC Staff Advocacy Letter to Sen. Chip Shields, Oregon State Legislature, Concerning Proposed Bill to Provide Antitrust Immunity for Certain Health Care Information Exchanges and Agreements (May 18, 2015)

Appendix D167. FTC Staff Advocacy Letter to Hon. Michael Ranzenhofer, New York State Senate, and Hon. Thomas Abinanti, New York State Assembly, Concerning a Bill to Authorize Health Care Hospital Collaboration (June 5, 2015)

Appendix D168. FTC Staff Advocacy Letter to Hon. Joe Hoppe and Hon. Melissa Hortman, Minnesota House of Representatives, Concerning a Bill to Permit the Disclosure of Competitively Sensitive Health Care Information (June 29, 2015)

Appendix D169. FTC Staff Advocacy Letter to Hon. Marilyn W. Avila, North Carolina House of Representatives, Concerning a Bill to Modify North Carolina Certificate-of-Need Law (July 10, 2015)

Appendix D170. FTC Staff Advisory Letter to Susan Puglisi, Virginia Department of Health Concerning Virginia Rules and Regulations Governing Cooperative Agreements (Sept. 17, 2015)

Appendix D171. FTC Staff Advocacy Letter to Malaka Watson, Tennessee Department of Health, Concerning Tennessee Rules Implementing Laws Relative to Cooperative Agreements and Certificates of Public Advantage (Sept. 24, 2015)

Appendix D172. Joint Statement of the FTC and Antitrust Division to the Virginia Certificate of Need Work Group (Oct. 26, 2015)

Appendix D173. FTC Advocacy Letter to Jenny A Horne, South Carolina House of Representatives, Concerning Proposed Legislation Relating to Supervision of Advanced Practice Nurses (Nov. 2, 2015)

Appendix D174. Joint Statement of the FTC and Antitrust Division on Certificate-of-Need Laws and Proposed South Carolina Legislation (Jan.16, 2016)

Appendix D175. FTC Advocacy Letter to Hon. Valencia Seay, Georgia State Senate, Concerning a Bill Relating to the Supervision of Dental Hygienists (Jan. 29, 2016)

Appendix D176. FTC Staff Advocacy Letter to Hon. Kent Leonhardt, Senate of West Virginia, Concerning a Bill to Place Regulation of Advanced Practice Registered Nurses under the State Board of Medicine and Osteopathy (Feb. 10, 2016)

Appendix D177. FTC and Department of Justice Advocacy Letter to Hon Bradley H. Jones, Jr., Massachusetts House of Representatives, Concerning a Bill Permitting Optometrists to Treat Glaucoma Patients (Feb. 18, 2016)

Appendix D178. FTC Staff Advocacy Letter to Hon. Mike Pushkin, West Virginia House of Delegates, Concerning a Bill Providing State-Action Protection to Certain Health-Care Collaborative Activity (Mar. 9, 2016)

Appendix D179. FTC Advocacy Letter to Rep. Steve Thompson, Alaska State Legislature, Concerning a Bill Permitting Telehealth Services (Mar. 25, 2016)

Appendix D180. FTC Advocacy Letter to Hon. Tim Burch, Kentucky House of Representatives, Concerning a Bill Regulating Denturists (Mar. 25, 2016)

Appendix D181. FTC Staff Advocacy Letter to Larry C. Stutts, Alabama State Senate Concerning Antitrust Exemption for Public University Medical School Collaboration Agreements (May 2, 2016)

Appendix D182. Joint Comments of the FTC and U.S. Department of Justice to the Puerto Rico House of Representatives Concerning a Bill Expanding the Practice Scope of Optometrists (May 18, 2016)

Appendix D183. FTC Advocacy Letter to the Veterans Administration Concerning Proposed Rule on Advanced Practice Registered Nurses Restrictions (July 25, 2016)

Appendix D184. FTC Staff Advocacy Letter to the

Delaware Board of Occupational Therapy Practice Concerning Occupational Therapist Telehealth Supervision (Aug. 3, 2016)

Appendix D185. FTC Staff Advocacy Letter to the Delaware Board of Dietetics/Nutrition Concerning Provision of Telehealth Dietetic and Nutrition Services (Aug. 16, 2016)

Appendix D186. FTC Advocacy Letter to the Delaware Board of Speech/Language Pathologists, Audiologists, and Hearing Aid Dispensers Concerning Amendment to Telecommunication and Telehealth Regulations (Nov. 29, 2016)

Appendix D187. FTC Staff Advocacy Letter to Hon. Peggy Lehner, Ohio State Senate, Concerning a Bill to License Dental Therapists (Mar. 3, 2017)

Appendix D188. FTC Staff Advocacy Letter to Hon. Suzanne Geist, Nebraska State Senate, Concerning a Bill to Eliminate Certain Occupational Licensing Requirements (Mar. 15, 2017)

Appendix D189. Joint Statement of the Antitrust Division and the FTC on Certificate-of-Need Laws and Alaska Senate Bill 62 (Apr. 7, 2017)

Appendix D190. FTC Advocacy Letter to Hon. Frank W. Berry Concerning Certificate of Need Application (Oct. 16, 2017)

Appendix D191. FTC Advocacy Letter to Hon. Jesse Topper, Pennsylvania House of Representatives Concerning Certified Nurse Practitioners (Jan. 3, 2018)

Appendix D192. Statement of the Federal Trade Commission to the Alaska Senate Committee on Labor & Commerce on Certificate-of-Need Laws and Alaska Senate Bill 62 (Feb. 6, 2018)

Appendix D193. FTC Staff Comment to Washington

State Rep. Paul Graves, Regarding S.S.B. 5411/H.B. 1473 (Feb. 9, 2018)

Appendix D194. FTC Staff Comment on New York's Proposal to Allow Licensure by Endorsement of Canadian Dental Licenses (April 6, 2018)

Appendix D195. Letter From Markus H. Meier, Assistant Director, Bureau of Competition, Concerning Crouse Health Hospital's Proposal To Sell Discounted Pharmaceutical Products to the Employees, Retirees, and Their Dependents of Its Affiliate, Dated October 20, 2017

Appendix D196. Guidance From Staff of the Bureau of Competition's Health Care Division on Requesting and Obtaining an Advisory Opinion

Appendix D197. FTC Press Release: Multilateral Pharmaceutical Merger Task Force Seeks Public Input (May 11, 2021)

Appendix D198. FTC Order to File a Special Report, (January 13, 2021)

Appendix D199. FTC Staff Advisory Opinion Letter from Markus Meier to Doylestown Health Foundation—Staff Opinion Letter Concerning Discounted Pharmaceuticals and Medical Devices Under the Non-Profit Institutions Act (September 2, 2021)

Appendix D200. FTC Staff Policy Paper: FTC Policy Perspectives on Certificates of Public Advantage (August 15, 2022)

Appendix D201. Federal Trade Commission Staff Submission to New York State Health Department Regarding the Certificate of Public Advantage Application of State University of New York Upstate Medical University and Crouse Health System, Inc. (October 7, 2022)

Appendix D202. FTC Amicus Brief in Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals, 1:21-cv-00691-GBW (D. Del)

Appendix D203. Summary Report on the FDA/FTC Workshop on a Competitive Marketplace for Biosimilars (Posted February 28, 2023; date on publication: March 9, 2020)

Appendix D204. Federal Trade Commission and Department of Justice's 44th Hart-Scott-Rodino Annual Report (FY2021) (February 2023)

Appendix D205. FTC Staff Comment Regarding North Carolina Senate Bill 743, Purporting to Give State Action Defense to UNC Health's Collaborative Activities (June 5, 2023)

Appendix D206. FTC Amicus Brief in *In re Bystolic Antitrust Litigation* (June 20, 2023)

Appendix D207. Federal Trade Commission Statement Concerning Reliance on Prior PBM-Related Advocacy Statements and Reports That No Longer Reflect Current Market Realities (July 20, 2023)

Appendix D208. Hart-Scott-Rodino Annual Report - Fiscal Year 2024 (9-17-25)

Appendix D209. FTC Clarke Edwards Letter to Senator Brad Hutto (SC) Regarding S.45 / H.3580 and S.669 (Regarding practice of Advanced Practice Registered Nurses ("APRNs") (9-9-25)

PART III

APPENDICES

Appendix E

Appendix E.	Speeches
Appendix E1.	"Joint Ventures in Evolving Health Care Markets," Mark J. Horoschak, Assistant Director, Bureau of Competition, Federal Trade Commission (Sept. 25, 1993)
Appendix E2.	"The Health Care Guidelines and Associations—How Associations Can Work with the Department of Justice," Anne K. Bingaman, Assistant Attorney General, Antitrust Division (Feb. 16, 1994)
Appendix E3.	"State Action Immunity for Health Care Collaboration after *FTC v. Ticor,"* Mark D. Whitener, Acting Deputy Director, Bureau of Competition, Federal Trade Commission (Apr. 6, 1994)
Appendix E4.	Remarks of Mary Lou Steptoe, Acting Director, Bureau of Competition, Federal Trade Commission, on Premerger Collaboration (Apr. 7, 1994)
Appendix E5.	"Combination and Collaboration in Health Care Markets: Antitrust as a Constraint in a Time of Change," Mark D. Whitener, Acting Deputy Director, Bureau of Competition, Federal Trade Commission (Apr. 28, 1994)
Appendix E6.	"Efficiency Justifications for Hospital Mergers," Mary Lou Steptoe, Acting Director, Bureau of Competition, Federal Trade Commission (June 17, 1994)

Appendix E7. "Recent Developments in the FTC's Antitrust Program for Health Care Markets," Mark J. Horoschak, Assistant Director, Bureau of Competition, Federal Trade Commission (Feb. 16, 1995)

Appendix E8. "Current Issues in Health Care Antitrust: Boycotts, Mergers, and Provider Networks," Mary Lou Steptoe, Acting Director, Bureau of Competition, Federal Trade Commission (April 5, 1995)

Appendix E9. "Integrated Joint Ventures," Mary L. Azcuenaga, Commissioner, Federal Trade Commission (Aug. 7, 1995)

Appendix E10. "Vertical Restraints With Horizontal Consequences: Competitive Effects of 'Most Favored Customer' Clauses," Jonathan B. Baker, Director, Bureau of Economics, Federal Trade Commission (Sept. 28, 1995)

Appendix E11. Statement of Robert Pitofsky, Chairman, Federal Trade Commission, Before the Committee on the Judiciary, U.S. House of Representatives (Feb. 27, 1996)

Appendix E12. "Antitrust Analysis of Hospital Networks and Shared Services Arrangements," Robert L. Leibenluft, Assistant Director, Bureau of Competition, Federal Trade Commission (Oct. 10, 1996)

Appendix E13. "Comments on the Nuts and Bolts of a Civil Antitrust Investigation by the Department of Justice Involving the Healthcare Industry," Mark J. Botti, Trial Attorney, Health Care Task Force Antitrust Division (Oct. 25, 1996)

Appendix E14. "Current Issues in Health Care Antitrust Enforcement at the Federal Trade Commission," William J. Baer, Director, Bureau of Competition, Federal Trade Commission

Appendix E15. "A Stepwise Approach to Antitrust Review of Horizontal Agreements," Joel I. Klein, Assistant Attorney General, Antitrust Division (Nov. 7, 1996)

Appendix E16. Twenty-Five Years of State Antitrust Enforcement Applied to Health Care

Appendix E17. Sheila F. Anthony, Commissioner, Federal Trade Commission, "Use Your Time Wisely: Do's and Don't's for Effective Advocacy Before the Federal Trade Commission," text of remarks before the ABA Section of Antitrust Law Annual Meeting, New York, New York (July 11, 2000)

Appendix E18. "Antitrust Issues in Settlement of Pharmaceutical Patent Disputes," Prepared Remarks of Thomas B. Leary, Commissioner, Federal Trade Commission, before the Sixth Annual Health Care Antitrust Forum, Northwestern University School of Law, Chicago, Illinois, November 3, 2000

Appendix E19. "Antitrust Issues in the Settlement of Pharmaceutical Pattent Disputes," Part II, Thomas B. Leary

Appendix E20. Antitrust Division Health Care Business Review Letters Issued (Feb. 5, 2002)

Appendix E21. Prospective Guidance FTC Advisory Opinions (June 26, 2002)

Appendix E22. Prepared Statement of Timothy J. Muris, Chairman, Federal Trade Commission, before the Committee on Energy and Commerce, Subcommittee on Health, United States House of Representatives, Relating to the Pharmaceutical Industry (Oct. 9, 2002)

Appendix E23. Timothy J. Muris, Chairman, Federal Trade Commission, "The Interface of Competition and Consumer

Protection," Prepared Remarks before The Fordham Corporate Law Institute's 29th Annual Conference on International Antitrust Law and Policy (Oct. 31, 2002)

Appendix E24. Thomas B. Leary, Commissioner, Federal Trade Commission, "Efficiencies and Antitrust: A Story of Ongoing Evolution," Prepared Remarks before the ABA Section of Antitrust Law 2002 Fall Forum (Nov. 8, 2002)

Appendix E25. Timothy J. Muris, Chairman, Federal Trade Commission, "Everything Old Is New Again: Health Care and Competition in the 21st Century," Prepared Remarks before the Northwest University School of Law Seventh Annual Competition in Health Care Forum (Nov. 7, 2002)

Appendix E26. Timothy J. Muris, Chairman, Federal Trade Commission, Prepared Statement of the Federal Trade Commission on the Pharmaceutical Industry Before the Committee of the Judiciary, United States Senate (June 17, 2003)

Appendix E27. Thomas B. Leary, Commissioner, FTC, "Antitrust in Healthcare: A Keynote Address," Prepared Remarks Before the ABA Antitrust Law Section and the American Health Lawyers Association, Forum on Antitrust and Healthcare (May 15, 2003)

Appendix E28. Susan A. Creighton, Director, Bureau of Competition, FTC, "Diagnosing Physician-Hospital Organizations," Prepared Remarks Before the American Health Lawyers Association Program on Legal Issues Affecting Academic Medical Centers and Other Teaching Institutions (Jan. 22, 2004)

Appendix E29. FTC Statement in Closing Investigation

of Caremark Rx/AdvancePCS Merger (Feb. 11, 2004)

Appendix E30. Antitrust Division Statement on the Closing of its Investigation of Anthem, Inc.'s Acquisition of WellPoint Health Networks, Inc. (March 9, 2004)

Appendix E31. Antitrust Division Background of Closing Investigation of UnitedHealth Group's Acquisition of Oxford Health Plans (July 20, 2004)

Appendix E32. Pamela Jones Harbour, Commissioner, Federal Trade Commission, "A 'Check-Up' of Selected Health Care Activity at the Federal Trade Commission," Prepared Remarks Before the ABA Antitrust Law Section Spring Meeting (Mar. 30, 2005)

Appendix E33. Federal Trade Commission, "New Entry Into Hospital Competition," Prepared Testimony Before the Subcommittee on Federal Financial Management, Government Information, and International Security of the Committee on Homeland Security and Governmental Affairs of the U.S. Senate (May 24, 2005)

Appendix E34. William Blumenthal, General Counsel, Federal Trade Commission, "The Rhetoric of Gun Jumping," Prepared Remarks Before the Association of Corporate Counsel Annual Antitrust Seminar of Greater New York Chapter (Nov. 10, 2005)

Appendix E35. U.S. Department of Justice Statement on the Closing of the Vermont Home Health Investigation (Nov. 23, 2005)

Appendix E36. Jon Leibowitz, Commissioner, FTC, "Exclusion Payments to Settle Pharmaceutical Patent Cases: They're B-a-c-k!," Prepared Remarks Before the Second Annual In-House Counsel's Forum on Pharmaceutical Antitrust (Apr. 24, 2006)

Appendix E37. Prepared Statement of the FTC Before the Special Committee on Aging, U.S. Senate Concerning Barriers to Generic Entry (July 20, 2006)

Appendix E37A. David P. Wales, Deputy Director, Bureau of Competition, FTC, "Examining Competition in Group Health Care," Prepared Statement of the FTC Before the U.S. Senate Committee on the Judiciary (Sept. 6, 2006)

Appendix E38. J. Thomas Rosch, Commissioner, FTC, "Monopsony and the Meaning of 'Consumer Welfare': A Closer Look at *Weyerhaeuser*," Prepared Remarks Before the 2006 Milton Handler Annual Antitrust Review (Dec. 7, 2006)

Appendix E39. Mark Botti, Chief, Litigation I Section, Antitrust Division, "Competition in Healthcare and Certificate of Need," Prepared Testimony Before the General Assembly of the State of Georgia (Feb. 23, 2007)

Appendix E40. Mark J. Botti, Former Chief, Litigation I Section, Antitrust Division, "Observations on and From the Antitrust Division's Buyer-Side Cases: How Can 'Lower' Prices Violate the Antitrust Laws?", Prepared Remarks Before the ABA Section on Antitrust Law Spring Meeting (Apr. 19, 2007)

Appendix E41. Ryan Danks, Trial Attorney, & Joseph M. Miller, Acting Chief, Litigation I Section, Antitrust Division, "*U.S. v. AzHAA*: When Does a Group Purchasing Organization Become an Illegal Monopsonist?," Prepared Remarks Before the AHLA Annual Meeting (June 26, 2007)

Appendix E42. J. Thomas Rosch, Commissioner, FTC, "Clinical Integration in Antitrust: Prospects for the Future," Prepared

Remarks Before the AHLA and ABA Antitrust and Health Law Section 2007 Antitrust in Health Care Seminar (Sept. 17, 2007)

Appendix E43. David Wales, Deputy Director, Bureau of Competition, FTC, Prepared Statement of the FTC Before the House Judiciary Committee Concerning HR 971, "The Community Pharmacy Fairness Act of 2007" (Oct. 18, 2007)

Appendix E44. "Critical Loss Analysis: A Merger Lawyer's View," Prepared Slides of Jeffrey Schmidt, Director, Bureau of Competition, FTC, Before the ABA Section of Antitrust 2007 Fall Forum (Nov. 16, 2007)

Appendix E45. Prepared Statement of the FTC Before the Alaska House of Representatives Concerning Certificate of Need (Feb. 15, 2008)

Appendix E46. Prepared Statement of the Federal Trade Commission to the Florida Senate Concerning Certification of Need (Apr. 2, 2008)

Appendix E47. J. Thomas Rosch, Commissioner, FTC, "Litigating Merger Challenges: Lessons Learned," Prepared Remarks Before the Bates White Fifth Annual Antitrust Conference (June 2, 2008)

Appendix E48. J. Thomas Rosch, Commissioner FTC, "Enforcement Strategies in the Health Care Industry," Prepared Remarks Before the ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008)

Appendix E49. J. Thomas Rosch, Commissioner, FTC, "How Pay-for-Delay Settlements Make Consumers and the Federal Government Pay More for Much Needed Drugs," Prepared Statement of the FTC Before the Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and

Commerce, U.S. House of Representatives (Mar. 31, 2009)

Appendix E50. Richard A. Feinstein, Director, Bureau of Competition, FTC, "Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry: Why Consumers and the Federal Government Are Paying Too Much for Prescription Drugs," Prepared Statement of the FTC Before the Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate (June 3, 2009)

Appendix E51. Pamela Jones Harbour, Commissioner, FTC, "Clinical Integration: The Changing Climate and What It Means for Care Coordination," Prepared Remarks Before the American Hospital Association Annual Membership Meeting (Apr. 27, 2009)

Appendix E52. Jon Leibowitz, Chairman, FTC, " 'Pay-for-Delay' Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers' Wallets, and Help Pay for Health Care Reform (The $35 Billion Solution)," Prepared Remarks Before the Center for American Progress (June 23, 2009)

Appendix E53. Richard A. Feinstein, Director, Bureau of Competition, FTC, "The Importance of Competition and Antitrust Enforcement to Lower-Cost, Higher-Quality Health Care," Prepared Statement of the FTC Before the Senate Subcommittee on Consumer Protection, Product Safety, and Insurance (Jul. 16, 2009)

Appendix E54. J. Thomas Rosch, Commissioner, FTC, "Pay-for-Delay Settlements, Authorized Generics, and Follow-On Biologics: Thoughts on How Competition Law Can Best Protect

Consumer Welfare in the Pharmaceutical Context" (Nov. 19, 2009)

Appendix E55. Richard A. Feinstein, Director, Bureau of Competition, FTC, "Statement of Bureau of Competition Director on the FTC's Closure of Its Investigation of Consummated Hospital Merger in Temple, Texas" (Dec. 23, 2009)

Appendix E56. Department of Justice Press Release Concerning the Proposed Merger of Blue Cross of Michigan and Physicians Health Plan of Mid-Michigan (Mar. 8, 2010)

Appendix E57. Christine A. Varney, Assistant Attorney General, Antitrust Division, "Antitrust and Healthcare," Prepared Remarks Before the ABA/AHLA Antitrust in Healthcare Conference (May 24, 2010)

Appendix E58. Jon Leibowitz, Chairman, FTC, "A Doctor and a Lawyer Walk into a Bar: Moving Beyond Stereotypes," Prepared Remarks Before the American Medical Association (June 14, 2010)

Appendix E59. J. Thomas Rosch, Commissioner, FTC, The Antitrust/Intellectual Property Interface: Thoughts on How To Best Wade Through the Thicket in the Pharmaceutical Context (Nov. 17, 2010)

Appendix E60. Richard A. Feinstein, Director, Bureau of Competition, FTC, Prepared Statement of the Federal Trade Commission Before the Committee on the Judiciary, Subcommittee on Courts and Competition Policy, U.S. House of Representatives, on Antitrust Enforcement in the Health Care Industry (Dec. 1, 2010)

Appendix E61. Sharis A. Pozen, Chief of Staff, Antitrust Division, Statement Before the Committee on the Judiciary,

Subcommittee on Antitrust, Competition Policy, and Consumer Rights, U.S. Senate (Dec. 1, 2010)

Appendix E62. Edith Ramirex, Commissioner, FTC, "Antitrust, Accountable Care Organizations, and the Promise of Health Care Reform," Text of Keynote Address Before the 11th Annual Loyola Antitrust Colloquium (Apr. 29, 2011)

Appendix E63. Statement of J. Thomas Rosch, Commissioner, FTC, Respecting Proposed Regulations Implementing the Affordable Care Act (Mar. 3, 2011)

Appendix E64. Statement of Bureau of Competition Director Richard Feinstein on the Abandonment by Providence Health & Services of Its Plan to Acquire Spokane Cardiology and Health Clinics Northwest (April 8, 2011)

Appendix E65. J. Thomas Rosch, Commissioner, FTC, "Patent Settlements, Patent Reform, and Mergers: Recent Developments in Pharmaceutical Antitrust," Text of Remarks Before the Sixth Annual In-House Counsel Forum on Pharmaceutical Antitrust (May 11, 2011)

Appendix E66. "Oversight of the Antitrust Enforcement Agencies," Prepared Statement of the FTC Before the U.S. House of Representatives (Dec. 7, 2011)

Appendix E67. J. Thomas Rosch, Commissioner, FTC, "Antitrust Evaluation of Pay-for-Delay Settlements: A Persistent Quest for Balance," Text of Remarks Before the American Conference Institute's Paragraph IV Dispute Conference (Dec. 7, 2011)

Appendix E68. J. Thomas Rosch, Commissioner, FTC, "The One-Size-Fits-All Approach of the Affordable Care Act," Text of Remarks Before the 2012

InterSession Health Policy Symposium, Cornell University Sloan Program in Health Administration (Jan. 19, 2012)

Appendix E69. Remarks of Julie Brill, Commissioner, FTC, Before the North Carolina Bar Association's Antitrust and Trade Regulation Section (Feb. 9, 2012)

Appendix E70. Sharis A. Pozen, Acting Assistant Attorney General, "Competition and Health Care: A Prescription for High-Quality, Affordable Care," Text of Remarks Before the World Annual Leadership Summit on Mergers and Acquisitions in Health Care (Mar. 19, 2012)

Appendix E71. Prepared Statement of the FTC Before the U.S. House of Representatives Concerning H.R. 1946, the "Preserving Our Hometown Independent Pharmacies Act of 2011" (Mar. 29, 2012)

Appendix E72. J. Thomas Rosch, Commissioner, FTC, "Consummated Merger Challenges—The Past is Never Dead," Text of Remarks Before the ABA Section of Antitrust Law Spring Meeting (Mar. 29, 2012)

Appendix E73. Statement of the FTC Concerning the Proposed Acquisition of Medco Health Solutions by Express Scripts, Inc. (Apr. 2, 2012)

Appendix E74. Statement of the Department of Justice's Antitrust Division on its Decision to Close its Investigation of Highmark's Affiliation Agreement with West Penn Allegheny Health System (Apr. 10, 2012)

Appendix E75. Julie Brill, Commissioner, FTC, "Bending the Cost Curve: The View from the Federal Trade Commission," Health Care Ground Rounds (Jul. 30, 2012)

Appendix E76. Statement of the FTC Before the Joint

Committee on Health, West Virginia Legislature, Concerning Advanced Practice Registered Nurses (Sept. 10, 2012)

Appendix E77. J. Thomas Rosch, Commissioner, FTC, "Pharmaceutical Patent Settlements and the Supreme Court," Prepared Remarks Before CBI's 2nd Annual Life Sciences Compliance, Legal, and Regulatory Congress (Sept. 21, 2012)

Appendix E78. J. Thomas Rosch, Commissioner, FTC, "Returning the State Action Doctrine to its Moorings," Prepared Remarks for the Lewis Bernstein Memorial Lecture, St. John's University School of Law (Oct. 3, 2012)

Appendix E79. Antitrust Division Press Release, "Amerigroup Corp's Divestiture of its Virginia Operations Addresses Department of Justice's Concerns with WellPoint Inc.'s Proposed Acquisition of Amerigroup (Nov. 28, 2012)

Appendix E80. "Looking Back to Move Forward: Preserving the Progressive Tradition at the FTC Keynote Address" by Commissioner Edith Ramirez, New York State Bar Association Antitrust Law Section Dinner New York, New York (January 24, 2013)

Appendix E81. Maureen K. Ohlhausen, Commissioner, FTC, "Hospital Consolidation: The Good, The Bad, and The Ugly," Text of Remarks Before the 2013 National Policy Forum, America's Health Insurance Plans (Mar. 13, 2013)

Appendix E82. Federal Trade Commission/Department of Justice ACO Working Group, "Summary of Activities Following Issuance of the Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program" (Apr. 10, 2013)

Appendix E83. Federal Trade Commission/Department of Justice ACO Working Group, "Questions and Answers Relating to Data Used to Calculate Primary Service Area Shares Under the ACO Policy Statement" (Apr. 10, 2013)

Appendix E84. Julie, Brill, Commissioner, FTC, "Promoting Healthy Competition in Health Care Markets: Antitrust, the ACA, and ACOs," Text of Remarks Before the 2013 National Summit on Provider Market Power (June 13, 2013)

Appendix E85. Edith Ramirez, Chairwoman, FTC, "Prepared Statement of the FTC Before U.S. Senate Committee on the Judiciary on Pay-for-Delay Deals: Limiting Competition and Costing Consumers" (Jul. 23, 2013)

Appendix E86. Maureen K. Ohlhausen, Commissioner, FTC, "Section 5: Principles of Navigation," Before the U.S. Chamber of Commerce, Washington, D.C. (July 25, 2013)

Appendix E87. Maureen K. Ohlhausen, Commissioner, FTC, "Protecting Consumer Welfare in the U.S. Health Care Sector," Before the Mentor Group Forum for EU-US Legal-Economic Affairs, Berlin, Germany (Sept. 13, 2013)

Appendix E88. Joshua D. Wright, Commissioner, FTC, "Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission," Before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013)

Appendix E89. Joshua D. Wright, Commissioner, FTC, "The FTC's Role in Shaping Antitrust Doctrine: Recent Successes and Future Targets," Before the 2013 Georgetown Global Antitrust Symposium Dinner, Washington, D.C. (Sept. 24, 2013)

Appendix E90. Joshua D. Wright, Commissioner, FTC,

"FTC v. Actavis and the Future of Reverse Payment Cases," Before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013)

Appendix E91. Maureen K. Ohlhausen, Commissioner, FTC, "An Ounce of Antitrust Prevention Is Worth a Pound of Consumer Welfare: The Importance of Competition Advocacy and Premerger Notification," Before the Eleventh Annual Competition Day, Santiago, Chile (Nov. 5, 2013)

Appendix E92. Edith Ramirez, Chairwomen, Federal Trade Commission, "Oversight of the Enforcement of the Antitrust Laws," Before the U.S. House of Representatives, Washington, D.C. (Nov. 15, 2003)

Appendix E93. Aviv Nevo, Deputy Assistant Attorney General for Economics, Antitrust Division, "Mergers that Increase Bargaining Leverage," Before the Stanford Institute for Economic Policy Research and Cornerstone Research Conference on Highly Innovative Industries (Jan. 22, 2014)

Appendix E94. Maureen K. Ohlhausen, Commissioner, FTC, "Health Care Technology: Promoting Competition and Protecting Innovation," Text of Remarks before the Connecticut Bar Association Antitrust & Trade Regulation and Consumer Law Sections (Feb. 26, 2014)

Appendix E95. FTC, "Policy Perspectives: Competition and the Regulation of Advanced Practice Nurses" (Executive Summary) (Mar. 2014)

Appendix E96. Deborah L. Feinstein, Director, Bureau of Competition, FTC, "The Forward-Looking Nature of Merger Analysis," Text of Remarks (Feb. 6, 2014)

Appendix E97. Julie Brill, Commissioner, FTC, "Competition in Health Care

Markets," Text of Remarks Before the 2014 Hal White Antitrust Conference (June 9, 2014)

Appendix E98. Deborah L. Feinstein, Director, Bureau of Competition, FTC, "Antitrust Enforcement in Health Care: Proscription, Not Prescription," Text of Remarks Before the Fifth National Accountable Care Organization Summit (June 19, 2014)

Appendix E99. Edith Ramirez, Chairwoman, FTC, "Retrospectives at the FTC: Promoting an Antitrust Agenda," Text of Remarks Before the George Washington University Law School Merger Transactions Symposium (June 28, 2013)

Appendix E100. Martin Gaynor, Director, Bureau of Economics, FTC, "Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care," Text of Remarks Before the 2014 American Antitrust Institute Annual Conference

Appendix E101. Joshua D. Wright, Commissioner, FTC, "Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed Answers," Text of Remarks Before the ABA Masters Course VII (Oct. 10, 2014)

Appendix E102. Julie Brill, Commissioner, FTC, "What's Past is Prologue: FTC's Competition and Consumer Protection Priorities," Text of Remarks Before the ABA Fall Forum (Nov. 6, 2014)

Appendix E103. William J. Baer, Assistant Attorney General, Antitrust Division, "Origin of the Species: The 100 Year Evolution of the Clayton Act," Text of Remarks Before the ABA Clayton Act 100th Anniversary Symposium (Dec. 4, 2014)

Appendix E104. Andrew Gavil, Director, Office of Policy Planning, FTC, "Prepared Statement

of the FTC on Competition and the Potential Costs and Benefits of Professional Licensure," Before the Committee of Small Business, U.S. House of Representatives (Jul. 16, 2014)

Appendix E105. Jonathan Nuechterlein, General Counsel, FTC, "How the FTC Works: Lessons from the Commission's Supreme Court Trifecta," Text of Remarks Before the American University Administrative Law Review Annual Symposium (Mar. 20, 2015)

Appendix E106. Maureen K. Ohlhausen, Commissioner, FTC, "Reflections on the Supreme Court's *North Carolina Dental* Decision and the FTC's Campaign to Rein in State Action Immunity" (Mar. 31, 2015)

Appendix E107. Terrell McSweeny, Commissioner, FTC, Text of Remarks (Apr. 28, 2015)

Appendix E108. Prepared Statement of the FTC Before the U.S. House of Representatives, "Oversight of the Enforcement of the Antitrust Laws" (May 15, 2015)

PART III

APPENDICES

Appendix E

Appendix E109. Maureen K. Ohlhausen, Commissioner, FTC, "Brother, May I? The Challenge of Competitor Control over Market Entry," Text of Remarks Before the George Mason School of Law Global Antitrust Economics Conference (May 29, 2015)

Appendix E110. Julie Brill, Commissioner, FTC, "A Common Goal: The U.S. Federal Trade Commission's Healthcare Enforcement Program and Its Implications for ACOs," Text of Remarks Before the Sixth Annual Accountable Care Organization Summit Preconference (June 17, 2015)

Appendix E111. Maureen K. Ohlhausen, Commissioner, FTC, "When Regulation Protects Privilege Instead of People: Government Restraints of Trade-A Competition Enforcer's Perspective," Text of Remarks Before The Antitrust Enforcement Symposium 2015 of the Journal of Antitrust Enforcement (June 27, 2015)

Appendix E112. Deborah L Feinstein, Director, Bureau of Competition, FTC, "*FTC v. Sysco*: Old School Antitrust With Modern Economic Tools" Text of Remarks Before GCR Live (Sept. 18, 2015)

Appendix E113. Edith Ramirez, Chairwoman, FTC, "The Horizontal Merger Guidelines Five Years Later," Text of Remarks Before the Georgetown University Law Center Ninth Annual Global Antitrust

Enforcement Symposium (Sept. 29, 2015)

Appendix E114. Bill Baer, Assistant Attorney General, Antitrust Division, Text of Remarks Before the New Health Care Industry Conference: Integration, Consolidation, Competition in the Wake of the Affordable Care Act (Nov. 15, 2015)

Appendix E115. Prepared Statement of the Federal Trade Commission Before the United States Senate Committee on the Judiciary, "License to Compete: Occupational Licensing and the State Action Doctrine" (Feb. 2, 2016)

Appendix E116. Terrell McSweeny, Commissioner, FTC, "Reflections on an Active Year in Merger Enforcement" (Feb. 5, 2016)

Appendix E117. Prepared Statement of the Federal Trade Commission Before the United States Senate Committee on the Judiciary, "Oversight of the Enforcement of the Antitrust Law" (Mar. 9, 2016)

Appendix E118. Edith Ramirez, Chairwoman, FTC, Keynote Address Before the Antitrust in Health Law Conference (May 12, 2016)

Appendix E119. Statement of the Federal Trade Commission to the Alaska Senate Committee on Labor & Commerce on Certificate-of-Need Laws and SB 62 (February 6, 2018)

Appendix E120. Maureen K. Ohlhausen, Acting Chairman, FTC, "Advancing Economic Liberty," Text of Remarks Before the George Mason Law Review's 20th Annual Antitrust Symposium (Feb. 23, 2017)

Appendix E121. Maureen K. Ohlhausen, Acting Chairman, FTC, "Death By a Thousand Haircuts: Economic Liberty and Occupational Licensure Reform,"

Prepared Remarks Before the Heritage Foundation (Jul. 26, 2017)

Appendix E122. Maureen K. Ohlhausen, Acting Chairman, FTC, "Diagnosing the Treatments: Issues in Post-Patent Pharmaceutical Markets," Text of Opening Remarks from the FTC Workshop in Understanding Competition in Prescription Drug Markets (Nov. 8, 2017)

Appendix E123. Maureen K. Ohlhausen, Acting Chairman, FTC, "The First Wealth is Healing: Protecting Competition in Healthcare Markets," Text of Remarks Before the 2017 American Bar Association Antitrust Section Fall Forum (Nov. 16, 2017)

Appendix E124. Remarks at Credit Suisse 2018 Washington Perspectives Conference Washington DC (Jan. 10, 2018)

Appendix E125. Bernard A. Nigro, Jr., Deputy Assistant Attorney General, Antitrust Division, Text of Remarks as Prepared for the Antitrust in Healthcare Conference: A Prescription for Competition (May 17, 2018)

Appendix E126. Rebecca Kelly Slaughter, Commissioner, FTC, "Antitrust and Health Care Providers: Policies to Promote Competition and Protect Patients," Text of Remarks Before the Center for American Progress (May 14, 2019)

Appendix E127. Joseph J. Simons, Chairman, FTC, "A Health Care Check on COPAs: Assessing the Impact of Certificates of Public Advantage in Health Care Markets," Text of Remarks Before the FTC Workshop on Certificates of Public Advantage (June 18, 2019)

Appendix E128. Christine S. Wilson, Commissioner, FTC, "Bigger than 'Big Tech'? The Need to Reform Our Health Care System Using Choice and Competition," Text of Remarks Before

the 2019 Global Antitrust Enforcement Symposium (September 9, 2019)

Appendix E129. Keynote Remarks of Commissioner Christine S. Wilson at the Council for Affordable Health Coverage (January 16, 2020)

Appendix E130. Opening Remarks of Chairman Joseph Simons at FDA / FTC Biosimilars Workshop (March 9, 2020)

Appendix E131. Wilson says pandemic underscores need to establish privacy rules for 'Big Tech' (May 18, 2020)

Appendix E132. Occupational Licensing in Health Care: Sorting the Wheat from the Chaff (June 19, 2020)

Appendix E133. Statement of Commissioner Rebecca Kelly Slaughter Concerning the Contact Lens Rule (June 22, 2020)

Appendix E134. Statement of Commissioner Rohit Chopra regarding the Review of the FTC's Pharmaceutical Merger Enforcement Program (May 11, 2021)

Appendix E135. Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson regarding the Multilateral Pharmaceutical Merger Task Force (May 11, 2021)

Appendix E136. "Antitrust Applied: Hospital Consolidation Concerns and Solutions," Statement before the Committee on the Judiciary Subcommittee on Competition Policy, Antitrust, and Consumer Rights, U.S. Senate, by Martin Gaynor, E.J. Barone University Professor of Economics and Public Policy, Heinz College, Carnegie Mellon University (May 19, 2021)

Appendix E137. Statement of FTC Office of Public Affairs Director Lindsay Kryzak on District Court's Decision to Grant Preliminary Injunction Halting New

Jersey Hospital Merger (August 4, 2021)

Appendix E138. Concurring Statement of Commissioner Slaughter and Chair Khan regarding *FTC and State of Rhode Island v. Lifespan Corporation and Care New England Health System* (February 17, 2022)

Appendix E139. Remarks of Chair Lina M. Khan Regarding the 6(b) Study on Pharmacy Benefit Managers (February 17, 2022)

Appendix E140. Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding Lifespan Corporation and Care New England Health System (February 17, 2022)

Appendix E141. FTC Statement Regarding Termination of Attempted Merger of Rhode Island's Two Largest Healthcare Providers (March 2, 2022)

Appendix E142. FTC Statement of Federal Trade Commission Bureau of Competition Deputy Director John M. Newman on Federal Appeals Court Ruling Affirming Preliminary Injunction to Halt Merger of New Jersey Hospital Networks (March 22, 2022)

Appendix E143. "The Importance of Vigorous Antitrust Enforcement in Health Care" keynote speech by Deputy Assistant Attorney General Andrew Forman at the ABA's Antitrust in Healthcare Conference - Washington, DC - Friday, June 3, 2022

Appendix E144. Statement Of Commissioner Christine S. Wilson In the Matter of HSR Premerger Notification Commission File No. P110014 (February 07, 2023)

Appendix E145. Keynote Remarks of Commissioner Rebecca Kelly Slaughter at the FTC/DOJ Pharmaceutical Task Force Workshop (June 14, 2022)

Appendix E146. Prepared Statement of the Federal Trade Commission Before the United States Senate Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights "Oversight of the Enforcement of the Antitrust Laws" (September 20, 2022)

Appendix E147. Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro M. Bedoya On the Adoption of the Statement of Enforcement Policy Regarding Unfair Methods of Competition Under Section 5 of the FTC Act (November10, 2022)

Appendix F

Appendix F. Antitrust/Health Care Guidelines

Appendix F1. Statements of Antitrust Enforcement Policy in Health Care, Issued by the United States Department of Justice and the Federal Trade Commission [Withdrawn by DOJ February 2023]

Appendix F2. DOJ Letter to Maryland on Board Certification of Medical Physicians (September 10, 2018)

Appendix F3. Joint DOJ/FTC Letter to Tennessee on CON Laws (March 7, 2019)

Appendix F4. Joint DOJ/FTC Letter to Alaska on CON Laws (March 11, 2019)

Appendix F5. FTC and DOJ Frequently Asked Questions About Voluntary Expedited Review Under the Statement of Antitrust Enforcement Policy Regarding ACOs Participating in the Medicare Shared Savings Program (the "Policy Statement")

Appendix F6. Joint FDA-FTC Statement Regarding Collaboration to Advance Competition in the Biologic Marketplace (February 3, 2020)

Appendix F7. FTC Non-Compete Complaint Against Gateway Services, Inc. and Gateway US Holdings, Inc. (9-4-25)

Appendix F8. FTC Agreement Containing Consent Order Relating to Gateway Services, Inc. and Gateway US Holdings, Inc. (9-4-25)

Appendix F9. Statement of Chairman Andrew N. Ferguson Joined by Commissioner Melissa Holyoak In the Matter of Gateway Pet Memorial Services (9-4-25)

Appendix F10. Dissenting Statement of Commissioner Rebecca Kelly Slaughter Regarding Gateway Pet Memorial Services/West Coast (9-4-25)

Appendix F11. FTC Healthcare Non-Compete Warning Letter Template (9-10-25)

Appendix F12. FTC Complaint *In the Matter of Centerbridge Seaport Acquisition Fund, L.P.*

Appendix F13. Agreement Containing Consent Orders *In the Matter of Centerbridge Seaport Acquisition Fund, L.P.*

Appendix F14. Agreement Containing Consent Order for Express Scripts Defendants *In the Matter of (Insulin) Caremark Rx, Zinc Health Services, et al.*

Appendix F15. Letter from Office of Policy Planning Acting Director Clarke Edwards to Senator Juan Barnett Concerning Mississippi H.B. 1057 to Address the Practice of Advanced Practice Registered Nurses (January 25, 2026)

Appendix F16. Agreement Containing Consent Order with Respondents Caremark RX, LLC and Zinc Health Services, LLC (7-14-26)

Appendix F17. Proposed Final judgment—United States v. Edwards LifeSciences Corp. and Genesis MedTech Group, Ltd., Case 1:26-cv-02450 (D.D.C)

Appendix F18. Competitive Impact Statement—United States v. Edwards LifeSciences Corp. and Genesis MedTech Group, Ltd., Case 1:26-cv-02450 (D.D.C)

Appendix F19. Agreement Containing Consent Order—In the Matter of Aurobindo Pharma LTD, a corporation; Aurobindo USA Inc., a corporation; and Lannett Company, Inc., a corporation (6-18-26)

Appendix F20. Agreement Containing Consent Orders—In the Matter of Aurobindo Pharma LTD, a corporation; Aurobindo USA Inc., a corporation; and Lannett Company, Inc., a corporation. FTC Matter/File Number 251 0096; Docket Number C-4834

Appendix F21. Letter from Office of Policy Planning Director Brendan Chestnut et al. to Representative David Hawk Concerning Tennessee H.B. 2278/S.B. 2414 on the Expiration of Ballad Health COPA and H.B. 819/S.B. 1369 to Remove CON Requirements for Acute Care Hospitals (4-1-26)

Appendix G

Appendix G. Reference Materials on Antitrust Guidelines, Policy, and Regulatory Enforcement in Healthcare and General Competition

Appendix G1. Antitrust Guidelines for Collaborations Among Competitors (Issued Apr. 2000)

Appendix G2. Statement of Enforcement Principles Regarding "Unfair Methods of Competition" Under Section 5 of the FTC Act (Aug. 13, 2015)

Appendix G3. U.S. Department of Justice & Federal Trade Commission, Antitrust Guidance for Human Resource Professionals (Oct. 2016)

Appendix G4. DOJ and FTC Joint Antitrust Statement Regarding COVID-19 (Mar. 2020)

Appendix G5. Overview of FTC Actions in Health Care Services and Products (June 2026)

Appendix G6. Overview of FTC Actions in Pharmaceutical Products and Distribution (June 2026)

Appendix G7. FTC Topic and Yearly Indices of Health

Care Antitrust Advisory Opinions by Commission and by Staff (Dec. 2025)

Appendix G8. Summary of Antitrust Division Health Care Cases (Since Aug. 25, 1983) (2020)

Appendix G9. DOJ Antitrust Division Healthcare Matters Resolved Without a Case Filed (1983-2018)

Appendix G10. Complaint for Temporary Restraining Order and Preliminary Injunction Pursuant to Section 13(b) of the Federal Trade Commission Act [Redacted Public Version] (May 16, 2023)

Appendix G11. Testimony of Director William Montejo, RN Division of Licensing and Certification, Maine Department of Health and Human Services; In Support of LD 97, An Act to Repeal the Hospital and Health Care Provider Cooperation Act To the Joint Standing Committee on Health Coverage, Insurance, and Financial Services (Jan. 31, 2023)

Appendix G12. The Future of Pharmaceuticals: Examining the Analysis of Pharmaceutical Mergers; FTC-DOJ Workshop Summary (Jun. 1, 2023)

Appendix G13. DOJ Antitrust Division Economic Analysis Group Discussion Paper: Online Reviews and Hospital Choices, EAG 22-1 (Dec. 2022)

Appendix G14. *FTC v. Louisiana Children's Medical Center* Petition (Apr. 20, 2023)

Appendix G15. Stipulated Order for Permanent Injunction and Equitable Relief, *Federal Trade Commission, Plaintiff, v. Surescripts, LLC* (Jul. 26, 2023)

Appendix G16. Agreement Containing Consent Order, In the Matter of Amgen Inc. and Horizon Therapeutics plc, FTC File No. DO9414 (2023)

Appendix G17. Federal Complaint for Injunction, FTC v.

U.S. Anesthesia Partners, Inc. (Sep. 21, 2023)

Appendix G18. FTC Administrative Complaint in matter of Novant Health, Inc. and Community Health Systems, Inc. (Jan. 25, 2024)

Appendix G19. FTC Interim Staff Report on Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies (Jul. 2024)

Appendix G20. Statement of Chair Lina M. Khan Joined by Commissioners Alvaro M. Bedoya & Rebecca Kelly Slaughter Regarding the Pharmacy Benefit Managers Interim Staff Report (Jul. 9, 2024)

Appendix G21. Statement of Commissioner Rebecca Kelly Slaughter Regarding FTC Staff Interim Report: Pharmacy Benefit Managers (Aug. 1, 2024)

Appendix G22. Concurring Statement of Commissioner Andrew N. Ferguson Regarding the Pharmacy Benefit Managers Interim Staff Report (Jul. 9, 2024)

Appendix G23. Assistant Attorney General Jonathan Kanter Announces Task Force on Health Care Monopolies and Collusion (May 9, 2024)

Appendix G24. FDA Draft Guidance Biosimilar Drugs Comment Letter (Aug. 20, 2024)

Appendix G25. Administrative Complaint in Lawsuit *In the Matter of Caremark Rx, LLC; Zinc Health Services LLC; Express Scripts, Inc.; Evernorth Health, Inc.; Medco Health Services, Inc.; Ascent Health Services LLC; OptumRx, Inc.; OptumRx Holdings LLC; and Emisar Pharma Services LLC, Respondents,* FTC Matter/File Number 221 0114, Docket Number 9437 (Sept. 20, 2024)

Appendix G26. Statement of FTC Bureau of Competition Deputy Director Rahul Rao on Lawsuit Against PBMs and the Role of Drug Manufacturers in Distorting

Competition in the U.S Drug Distribution System (Sept. 20, 2024)

Appendix G27. Staff Submission to Indiana Health Department Regarding the Certificate of Public Advantage Application of Union Health and Terre Haute Regional Hospital (Sept. 5, 2024)

Appendix G28. DOJ Antitrust Division Evaluation of Corporate Compliance Programs in Criminal Antitrust Investigations (Nov. 2024)

Appendix G29. DOJ Complaint in matter of *U.S., et al. v. UnitedHealthGroup Incorporated, et al.,* 1:24-cv-03267-JKB, (D. MD)

Appendix G30. FTC Report: Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers (Jan. 14, 2025)

Appendix G31. Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro M. Bedoya In the Matter of Welsh, Carson, Anderson & Stowe (Jan. 17, 2025)

Appendix G32. Administrative Complaint In the Matter of GTCR BC Holdings, LLC and Surmodics, Inc., FTC Matter/File Number 241 0095, Docket Number 9440 (Mar. 6, 2025)

Appendix G33. Federal Trade Commission Supplemental Staff Submission to Indiana Health Department Regarding 2025 Certificate of Public Advantage Application of Union Health and Terre Haute Regional Hospital (Mar. 17, 2025)

Appendix G34. DOJ and FTC Antitrust Guidelines for Business Activities Affecting Workers (Jan. 2025)

Appendix G35. "Statement of Interest of the United States of America" in the case of *Duffy v. Yardi Systems, Inc.* (Mar. 1, 2024)

Appendix G36. Massachusetts Chapter 343 "An Act

Enhancing The Market Review Process" (Key Provisions in effect Apr. 8, 2025)

Appendix G37. Welsh, Carson, Anderson & Stowe, In the Matter of—Final Decision and Order (May 19, 2025)

Appendix G38. Administrative Complaint In the Matter of Edwards Lifesciences Corp. and JenaValve Technology, Inc., Docket No. 9442 (Aug. 6, 2025)

Appendix G39. Warning Letter to Covis Pharma GMBH (May 21, 2025)

Appendix G40. Letter to Azurity Pharmaceuticals (Jun. 2, 2025)

Appendix G41. Warning Letter to Teva Branded Pharmaceutical Products R&D, Inc. (May 21, 2025)

Appendix G42. Warning Letter to Teva Pharmaceutical Industries Ltd. c/o Teva (May 21, 2025)

Appendix G43. Warning Letter to Amphastar Pharmaceuticals Inc. (May 21, 2025)

Appendix G44. Warning Letter to Mylan Specialty LP (May 21, 2025)

Appendix G45. Warning Letter to Norton (Waterford) Limited (May 21, 2025)

Appendix G46. Warning Letter to Novartis Pharmaceuticals Corp. (May 21, 2025)

Appendix G47. Price Fixing, Bid Rigging, and Market Allocation Schemes: What They Are and What to Look For: An Antitrust Primer," published by the Department of Justice, Antitrust Division (Apr. 21, 2025)